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SOMMARIO 
 
/¶DQHPLD GD LQILDPPD]LRQH q XQ¶DQHPLD QRUPRFLWLFD H QRUPRFURPLFD DVVRFLDWD
ad un alterato metabolismo del ferro, a una eritropoiesi inefficace e a una ridotta 
sopravvivenza dei globuli rossi.  
/¶HSFLGLQD q XQ RUPRQH OD FXL VHFUH]LRQH q LQGRWWD da interleuchina-6, 
precedentemente identificDWRFRPHSHSWLGHDQWLPLFURELFR$WWXDOPHQWHO¶HSFLGLQDq
ULFRQRVFLXWDVLDFRPHLOSULQFLSDOHUHJRODWRUHGHOO¶RPHRVWDVLGHIHUURQHLPDPPLIHUL
GRYH QH FRQWUROOD LO PHWDEROLVPR VLD FRPH PRGXODWRUH FKLDYH GHOO¶DQemia da 
infiammazione. /¶HSFLGLQDYLHQHsecreta in circolo dagli epatociti e in quota minore 
viene prodotta anche da macrofagi, linfociti ed adipociti. 
Questo studio prospettico è stato condotto in 60 pazienti ospedalizzati per stati 
infiammatori acuti (95% affetti da infezioni acute), dei quali è stato ampiamente 
FDUDWWHUL]]DWRLOSURILORLQILDPPDWRULRORVWDWRGHOIHUURHO¶HULWURSRLHVL 
Sono state ottenute in vivo le medesime condizioni infiammatorie realizzate nei 
modelli di endotossiemia in vitro descritti da Kemna ed al. e da Theurl ed al. Inoltre, 
L OLYHOOLGLHSFLGLQDHPRJORELQDHGHOO¶DVVHWWRGHO IHUURRVVHUYDWHQHOQRVWURVWXGLR
sono molto simili ai dati descritti da van Eijk ed al. in pazienti con sepsi severa 
ospedalizzati in reparti di terapia intensiva.  
Infatti, anche nel nostro studio, lo stato di infiammazione acuta, definito da elevati 
livelli serici di proteina C-reattiva e interleuchina-6, era associato ad elevate 
concentrazioni di epcidina serica, bassa sideremia, elevata saturazione della 
transferrina e livelli molto alti di ferritina serica.  
Abbiamo osservato che la persistenza di livelli elevati di epcidina serica era 
associata a una riduzione dei livelli di emoglobina nel corso della prima settimana 
GLRVSHGDOL]]D]LRQH1HOO¶DUFRGHOODSULPDVHWWLPDQDO¶HULWURSRLHVLqULVXOWDWDHVVHUH
inefficace, nonostante i livelli di eritropoietina serica fossero molto elevati 
VRSUDWWXWWR QHL SD]LHQWL JLj DQHPLFL DOO¶LQJUHVVR 1  ,QROWUH TXHVWL SD]LHQWL
presentavano anche elevati livelli di GDF-15 ed epcidina. I pazienti che avevano 
QRUPDOL YDORUL GL HPRJORELQD DOO¶LQL]LR GHOO¶RVSHGDOL]]D]LRQH 1  KDQQR
sviluppato anemia nel corso della prima settimana. Analizzando i loro valori di 
epcidina, abbiamo individuato che una concentrazione di epcidina di 23 nM/L era 
un cut-RII LQJUDGRGLSUHGLUH O¶HYHQLHQ]DGL DQHPLDGRSRXQDVHWWLPDQDFRQXQD
sensibilità del 100% e una specificità del 90%. 
Come già descritto in altri studi, aEELDPR GLPRVWUDWR O¶HVSUHVVLRQH GL P51$
GHOO¶HSFLGLQDda parte dei monociti circolanti in questi pazienti con infiammazione 
acuta. In particolare abbiamo osservato che dopo una settimana di persistenza 
GHOO¶LQILDPPD]LRQH L OLYHOOL SL HOHYDWL GL P51$ GHOO¶HSFLGLQD HUDQR HVSUHVVL QHL
monociti circolanti dei pazienti che avevano uno stato infiammatorio più intenso, 
così come era più evidente una correlazione negativa tra i livelli di mRNA 
GHOO¶HSFLGLQDHVSUHVVRGDLPRQRFLWLHLOLYHOOLGLIHUULWLQDVHULFD 
/¶DQDOLVLnei monociti circolanti GHOUHFHWWRUHIXQ]LRQDOHGHOO¶LQWHUleuchina-6 (CD126 
and gp130) ha mostrato una correlazione negativa FRQ O¶espressione di mRNA 
GHOO¶HSFLdina e una correlazione positiva con i livelli di ferritina serica.  
La conoscenza deLPHFFDQLVPLPROHFRODULFKHVRWWHQGRQRO¶LQVWDXUDUVLGHOO¶DQHPLD
da infiammazione e il ruolo GHOO¶HSFLGLQDKDIRUQLWRQXRYLVWUXPHQWLGLDJQRVWLFLFKH
permettono una migliore diagnosi delle cause di anemia e una  terapia mirata. 
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SUMMARY 
 
The anaemia of inflammation is a normochromic, normocytic anaemia, associated 
with abnormal iron utilization, erythropoietin hyporesponsiveness, and decreased 
red blood cells (RBC) survival. It is a very common problem in hospitalized patients 
for acute inflammatory diseases and develops within few days from the onset of 
illness.  
Hepcidin is an interleukin-6 induced hormone previously identified as an 
antimicrobial peptide. Now it is recognized as the master regulator of iron 
homeostasis in mammals allowing iron adaptation according to the body iron needs 
and as the key modulator of inflammation-associated anaemia. Hepcidin is found in 
the circulation, it is secreted mainly by hepatocytes and to a lesser extent by 
macrophages, T-lymphocytes and adipocytes.  
In 60 acutely ill patients (95% affected by infections), the degree of inflammation, 
indicated by IL-6 and C-RP levels, is associated with elevated concentrations of 
hepcidin, low iron serum levels, high transferrin saturation and very high ferritin 
serum levels. Moreover, persistently increased levels of hepcidin-25 on T1 and on 
T6 are associated with a decrease in haemoglobin during hospitalization. Patients 
(N=26) anaemic on T1 were still anaemic after one week. Erythropoiesis was still 
blunted in these patients, despite higher erythropoietin serum levels than not-
anaemic patients. The high levels of GDF-15 and hepcidin could have a role in the 
ineffective erythropoiesis.  
We observed that acute ill patients (N=31) admitted with normal haemoglobin 
levels develop anaemia after the first week of hospitalization. Analysing hepcidin 
levels of this subset of patients, we found that a cut-off level of hepcidin 
concentration of 23 nM/L was able to predict anaemia occurrence after one week 
with 100% of sensitivity and 90% of specificity.  
The inflammatory cytokines pattern and its consequence on hepcidin and iron 
observed in vivo in this study resembles the one described in experimental models 
of endotoxemia showed by Kemna et al. and by Theurl et al. Also hepcidin serum 
levels, haemoglobin and iron parameters are very similar to the ones found by van 
Eijk et al. in their investigation in septic patients admitted to intensive care units 
As described in previous studies, we also demonstrated expression of hepcidin 
mRNA in circulating monocytes of these acutely ill patients. We found that the 
higher was the inflammation on admission, the higher was hepcidin mRNA 
expression in circulating monocytes after one week. Moreover we found negative 
correlation between mRNA levels of monocytes-derived hepcidin and serum 
ferritin, especially after one week of inflammation persistence. Analysis of 
interleukin-6 functional receptor (CD126 and gp130) on circulating monocytes 
showed a negative correlation with monocytes-derived hepcidin mRNA, and 
positive correlation with serum ferritin levels.  
These insights in anaemia of inflammation molecular mechanisms will help 
clinicians to better identify anaemia causes and adequately restore haemoglobin 
concentration with target therapies, reducing health-care requirements and 
healthcare costs, in-hospital stay and, finally, ameliorate health of patients. 
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1. INTRODUCTION 
 
The anaemia of inflammation (AI) is a very common problem in hospitalized 
patients for acute inflammatory diseases. It is a normochromic normocytic anaemia 
associated with abnormal iron utilization, erythropoietin hyporesponsiveness and 
decreased red blood cells survival that develops within few days from the onset of 
illness [1,2]. Approximately two-thirds of critically-ill patients present with a 
haemoglobin concentration less than 12 g/dl on admission in the intensive care unit 
(ICU), and 97% become anaemic by day 8 [3].  
Anaemia is only partially corrected during hospital. The prevalence of anaemia in 
patients being discharged after acute inflammation illness has been observed to be 
very high [4]. Anaemia may also be prolonged after the hospital stay. It has been 
observed that the median time to recovery of anaemia is 11 weeks and one study 
reported that more than half patients discharged by intensive care units are still 
anaemic after six months [5]. Anaemia is associated with worse outcomes (such as 
increased length of stay and increased mortality). Indeed, deleterious effects of 
anaemia include increased risk of cardiac related morbidity and mortality in 
critically ill and older patients [6]. 
 
The striking feature of AI is low serum iron (hypoferremia) in the presence of 
considerable amounts of iron in bone marrow macrophages, but these stores are 
still restricted iron available for erythropoiesis. Treatment of this form of anaemia 
can be a clinical challenge, since the inflammatory process interferes both with the 
delivery of iron to the bone marrow and with the action of erythropoietin (EPO) at 
its target sites in the bone marrow [7].  
 
Iron and immunity are closely linked. It has been suspected for some time that AI 
may be a side-effect of the host defence response to infection [8]. Indeed, many of 
the genes/proteins involved in iron homeostasis play a vital role in controlling iron 
fluxes such that bacteria are prevented from utilising iron for growth. Many studies 
in vitro and in animal models have recently elucidated the links of anaemia with 
inflammation and how the innate immunity effectively restricts iron availability to 
microbial invaders [9]. 
The regulation of hepcidin synthesis by cytokines (chiefly inteleukin-6) is the key 
link between host defence and iron metabolism, and an important component in 
the pathogenesis of AI. It has been observed that the cells of innate immune 
system, monocytes, macrophages and lymphocytes, are able to combat bacterial 
insults by carefully controlling their iron fluxes, which are mediated by hepcidin and 
ferroportin [10].  
 
1.1 Hepcidin 
 
1.1.1 Hepcidin Synthesis and Structure  
 
Human hepcidin is a 25±amino acid peptide hormone first identified in human urine 
and plasma by three separate groups investigating either novel anti-microbial 
peptides or iron regulation [11-13].  
It was named hepcidin (HEPC) because its mRNA was highly expressed in the 
liver and the peptide showed weak microbicidal activity in vitro [14,15]. Genetic 
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studies in mice identified the hepcidin pathway as a critical component in the 
control of iron homeostasis and now it is recognized as the master regulator of iron 
homeostasis in mammals allowing iron absorption and adaptation according to the 
body iron needs and as the main mediator of AI [14,16,17]  
Krause et al. [15], Park et al. [14], and Pigeon et al. [11] determined that the human 
hepcidin gene (HAMP; OMIM 606464, location 19q13.12) contains 3 exons, with 
the final exon encoding the active peptide. HAMP encodes an 84-residue 
prepropeptide that contains a 24-residue N-terminal signal peptide that is 
subsequently cleaved to produce the 60-amino acid pro-hepcidin that lacks iron-
regulatory activity.  
Prior to secretion, prohormone convertases cleave pro-hepcidin at a polybasic 
motif to generate the mature bioactive 25-amino acid hepcidin (Mr of 2789.4 Da) 
[11,15], that is secreted into the circulation. Subsequent amino-terminal processing 
of the 25 amino acid form can result in the appearance of 2 smaller hepcidin forms 
of 22 and 20 amino acids, also found in the urine.  
Mass spectrometry and chemical analysis have revealed that the structure of the 
bioactive 25±amino acid form of hepcidin is a simple hairpin with 8 cysteines that 
form 4 disulfide bonds in a ladder-like configuration, including an unusual disulfide 
bond that connects two adjacent cysteines (figure 1). 
 
  
 
Figure 1 ± A model structure of hepcidin-25 according to Jordan et al. [12] 
 
In vivo studies in mice have demonstrated that only full-length 25 amino acid 
hepcidin induces significant hypoferremia when injected intraperitoneally [18]. 
These findings are corroborated by in vitro studies that showed that the truncated 
22 amino acid and 20 amino acid forms have greatly diminished and almost 
complete loss of ferroportin regulatory activity, respectively, compared with 25 
amino acid hepcidin [19].  
 
1.1.2 Hepcidin kinetics 
 
Circulating hepcidin was recently found to be bound to alpha-2-macroglobulin with 
relatively high affinity and to albumin with relatively low affinity. On the basis of 
theoretical calculations, 11% of hepcidin was estimated to be freely circulating [20]. 
Whether binding to these carrier molecules influences the functional properties of 
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hepcidin is uncertain. Hepcidin clearance is assumed to occur via cellular co-
degradation with ferroportin at its sites of action (see below), and via excretion by 
the kidneys. 
 
1.1.3 Hepcidin, iron and inflammation 
 
The involvement of hepcidin in iron metabolism was suggested by the observation 
that hepcidin synthesis is induced by dietary iron [11]. The specific role of hepcidin 
was then examined by assessing the effects of its deficiency or excess in 
transgenic mouse models. These studies indicate that hepcidin inhibits intestinal 
iron absorption [21,22], placental iron transport [21], and release of recycled iron 
from macrophages [22], effectively decreasing the liver iron to maturing 
erythrocytes in the bone marrow (figures 2 and 3).  
 
  
 
Figure 2 ± The role of hepcidin in iron metabolism. 
 (From Nemeth E. et Ganz T. [23]) 
 
In humans, iron is an essential component of haemoglobin and myoglobin and of 
many enzymes involved in redox reactions and energy metabolism. Iron is strictly 
conserved, in large part by recycling the iron (about 20 mg/day) from haemoglobin 
of senescent erythrocytes. Most of the iron in plasma is destined for erythropoiesis 
in the bone marrow and hepcidin controls this iron flows through its receptor, 
ferroportin (figure 3) [24].  
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Figure 3 ± Hepcidin interaction with ferroportin controls the main iron flows into 
plasma. Iron flows and reservoirs are in blue, iron in haemoglobin in red, and 
hepcidin and its effect in orange.RBC: red blood cells; Fpn: ferroportin. 
 (From Ganz T. [24]) 
 
In humans, homozygous frameshift or nonsense mutations in hepcidin gene have 
been found in subjects affected by severe juvenile hemochromatosis [25]. Hepcidin 
production was also diminished in another form of juvenile hemochromatosis due 
to mutations in the hemojuvelin gene [26] and in the most common form of 
hemochromatosis, that caused by mutations in the HFE gene [27,28]. Autonomous 
overexpression of hepcidin mRNA expression was seen in large hepatic adenomas 
associated with iron-refractory anaemia [29] or mutations in a protein, 
transmembrane protease serine 6 (TMPRSS6) that leads to constitutive hepcidin 
over-expression develop a microcytic anaemia characterized by functional or actual 
iron deficiency associated with resistance to iron therapy called iron-refractory iron 
deficiency anaemia (IRIDA) [30]. 
 
It is now noteworthy that hepcidin levels are reliably elevated in patients with AI 
compared to normal values. Inflammation has a potent effect on iron homeostasis, 
reducing intestinal iron absorption, sequestering iron  in macrophages, and thereby 
decreasing serum iron levels.  In favor of the role of hepcidin in inflammatory 
hypoferremia, Nemeth et al stimulated in vitro fresh human hepatocytes with a 
panel of cytokines and showed strong induction of hepcidin mRNA by interleukin-6 
(IL-6), but not interleukin-1a (IL-1a) or tumor necrosis factor-alpha (TNF-alpha), 
indicating that IL-6 is the mediator of hepcidin induction by inflammation and 
hepcidin is a type II acute-phase response [28]. Moreover, urinary hepcidin level 
rose within hours of IL-6 or lipopolysaccharide (LPS) infusion into human 
volunteers, on the average 7-fold, and hypoferremia coincided with the rise of 
hepcidin. The maximal reduction in serum iron was evident some 2-4 h post-
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injection suggesting that the time course for the actions of hepcidin is similar both 
in vitro and in vivo [31].  
As confirm of the IL-6 as predominant inflammatory mediator of hepcidin 
expression, the addition in vitro of IL-6-QHXWUDOL]LQJ $E¶V WR KHSDWRF\WHV FXOWXUH
completely ablated the hepcidin increase induces by LPS or LPS-stimulated 
macrophages [31]. Other investigations on administration of inflammatory agents, 
such as Pseudomonas aeruginosa and group A Streptococcus, LPS, IL-1 or TNF-
alpha, demonstrated the hepcidin production in mice and/or in healthy human 
volunteers who develop normochromic, normocytic anaemia. Kemna et al. induced 
a cytokine response characteristic of inflammation with a dramatic increase in IL-6, 
that peaked at 3 to 4 hours after LPS injection in human volunteers [32]. 
Peyssonnaux et al. demonstrated the endogenous expression of hepcidin by 
macrophages and neutrophils in vitro and in vivo, in response to bacterial 
pathogens in a toll-like receptor 4-dependent fashion [33]. IL-6 directly regulates 
hepcidin (via IL-6/IL-6 receptor complex binding with gp130) through induction and 
subsequent promoter binding of signal transducer and activator of transcription 3 
(STAT3) [34,35]. The binding of this cytokine to its cellular receptor leads to the 
recruitment of Janus kinase 2 (JAK2), which phosphorylates STAT3; STAT3 is then 
translocated into the nucleus and binds to the STAT3 binding motif at -64/-72 in the 
hepcidin promoter region, which induces hepcidin transcription [36]. Figure 4 below 
details intracellular signaling pathway models [37]. 
 
 
 
Figure 4 ± Hepcidin and STAT3: balancing iron and inflammation. 
 (From Maliken et al. [37]) 
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Hepcidin exerts its activity by binding to the iron exporter ferroportin and causing its 
degradation. As ferroportin is the major entryway for iron into plasma, decrease in 
ferroportin reduces the extracellular iron available for erythropoiesis within hours 
and iron concentrations rapidly drop [18]. Hepcidin acts by inhibiting iron flows into 
plasma from macrophages involved in recycling of senescent erythrocytes, from 
duodenal enterocytes engaged in the absorption of dietary iron, and from 
hepatocytes that store iron [23]. Figure 5 details hepcidin fine tuning of the cells 
involved in systemic iron regulation [38]. 
 
 
 
Figure 5 ± Regulation of Systemic Iron Homeostasis. Cells involved in systemic 
iron regulation are shown. In iron overload (left), high hepcidin levels inhibit 
ferroportin-mediated iron export by triggering internalization and degradation of the 
complex to reduce transferrin saturation. Hepcidin expression is high. In iron 
deficiency (right), iron is released by ferroportin into the circulation. Haemoglobin-
derived heme is catabolized in macrophages by hemoxygenase-1 (HOX1). 
Hepcidin expression is low.(From Hentze et al. [38]) 
 
 1.1.4 Hepcidin and peripheral blood leukocytes 
 
Several studies have demonstrated hepcidin expression by cells other than 
hepatocytes, although at much lower levels by comparison [33,39-45]. The 
hepcidin produced by these cells may exert local effects in these tissues more than 
systemic influences. The amount of hepcidin found in the circulation is secreted 
mainly by hepatocytes, and to a lesser extent by macrophages, T-lymphocytes and 
adipocytes. 
Theurl et al. [46,47] showed that human monocytes hepcidin mRNA expression is 
induced within 3 hours after stimulation with LPS or IL-6. Hepcidin binding to its 
receptor ferroportin reduces iron availability, because induces hypoferremia, low 
serum iron-binding capacity and normal to elevated ferritin, thus controlling 
microbial growth. Pinto et al. [48] investigated the role of hepcidin in lymphocyte 
biology. They characterized the expression of hepcidin in human peripheral blood 
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lymphocytes (PBLs) and found that it increases after T-lymphocyte activation in 
vitro. Wu et al. [49] recently explored the expression and signaling mechanism 
regulating hepcidin mRNA expression in peripheral blood leukocytes. Ex vivo 
studies found that hepcidin mRNA expression in peripheral blood leukocytes 
induced by LPS depends on NF-kB, and TNF-a may be a key mediator in this 
procedure.  
 
1.1.5 Regulation of hepcidin 
 
Several physiologic and pathologic processes regulate the synthesis of hepcidin 
[38]. Situations in which demand for circulating iron is increased (particularly 
erythropoietic activity) elicit a decrease in hepatocellular hepcidin synthesis. On the 
other hand, infection and inflammation cause an increase in hepcidin synthesis. 
Figure 6 illustrates systemic and hepatic cellular regulatory mechanisms [50]. 
 
 
    
 
Figure 6 ± On the left: Iron (Fe) sufficiency and inflammation enhance hepcidin 
production in the liver. On the right: Signaling pathways for hepatic hepcidin 
transcription. (From Coyne DW. [50]) 
 
The functional signaling routes by which (a) iron status, (b) erythropoietic activity, 
(c) hypoxia, and (d) inflammation affect hepcidin expression are increasingly being 
investigated. These routes comprise 4 highly interconnected regulatory pathways 
(Figure 7). 
 
1.1.5.1 Regulation by erythropoietic signals 
Increased erythropoietic activity is a potent suppressor of hepcidin production. A 
single injection of erythropoietin in humans caused a dramatic decrease in serum 
hepcidin within 24 hours [51], and a mouse model showed a dose-dependent 
decrease in hepcidin mRNA after erythropoietin administration [52]. However, the 
signal that communicates the level of erythropoiesis to the liver to signal hepcidin 
suppression is not clear yet. Over-expression of serum transferrin receptor 
(sTFR1), which correlates well with erythroid mass and is responsive to iron 
deficiency, does not appear to alter iron metabolism in mice [53]. 
The hypothesis that erythropoietin (EPO) acts directly on hepatocyte receptors in 
cell culture [54] could not be confirmed in animal models for anaemia, which 
showed that decreased hepcidin expression depends on erythropoiesis and is not 
directly mediated by EPO [55,56]. 
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Recent observations suggest that the erythropoietic signal may include 1 or more 
proteins released at sites of active erythropoiesis, i.e., growth differentiation factor-
15 (GDF-15) and twisted gastrulation protein homolog-1 (TWSG1). These 
molecules, like bone morphogenetic proteins (BMP) are members of the 
transforming growth factor-family and thus possibly act through effects on the 
BMP/SMAD (mothers against decapentaplegic homolog ± Drosophila) pathway 
[57,58]. Tanno et al. [59] and colleagues recently demonstrated that GDF-15 is up-
regulated in thalassemic serum and can suppress hepcidin expression in vitro. 
Neither of these factors, however, appears to be required to mediate the decrease 
in hepcidin observed with EPO administration. It is likely that additional 
erythropoietic factors downregulating hepcidin expression suppression in vivo 
remain to be identified. 
 
1.1.5.2 Regulation by hypoxia 
Decreased hepcidin expression has been reported in response to hypoxia in vivo 
[31,60]. This effect might be attributable in part to the effect of hypoxia on EPO 
expression and then to an erythropoietic activity that has a possible direct 
interaction with hepatocyte receptors [54]. Alterations of the hypoxia-inducible 
transcription factor (HIF) pathway in vivo can affect hepcidin expression [61] but 
whether HIF regulates hepcidin transcription directly or mostly indirectly is still 
unresolved. The main effect of hypoxia on iron homeostasis is to increase 
erythropoietin production in the kidney, which would lead to proliferation of 
erythroblasts and suppression of hepcidin by putative erythroid factors [62].  
 
1.1.5.3 Regulation by inflammation 
Hepcidin synthesis is rapidly increased by infection and inflammation, causing 
retention of iron in macrophages and decreased iron absorption [63]. The resulting 
hypoferremia is presumably a component of innate immune responses that deprive 
invading microbes of iron and other essential nutrients. Serum hepcidin was found 
to be greatly increased in patients with inflammation defined as a value of C-
reactive protein >10 mg/dL, sepsis, burns, inflammatory bowel disease, and 
multiple myeloma [64-66]. As previously detailed, among the inflammatory 
mediators regulating hepcidin, IL-6 was shown to be a prominent inducer in vitro 
and in vivo, and it stimulates hepcidin transcription through a STAT-3 dependent 
mechanism (see above).  
In a proof-of-principle study, Sasu et al. neutralized hepcidin by a monoclonal 
antibody in the Brucella abortus mouse model of AI and found it to restore 
responsiveness to EPO [67]. The results of this study suggest that administration of 
anti-hepcidin therapies alone or in combination with erythropoiesis-stimulating 
agents may LPSURYHSDWLHQWV¶HU\WKURSRLHWLF UHVSRQVHDQGDOORZ WKHXVHRI ORZHU
EPO doses to avoid the potential detrimental effects of high EPO concentrations. 
Anti±IL-6 antibody was shown to suppress IL-6±induced hepcidin production in 
Castleman disease, and to improved anaemia in arthritic monkeys [68,69].  
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Figure 7 ± Molecular and functional pathways of hepatocyte hepcidin synthesis. 
(From Kroot et al. [70]) 
 
1.1.6 Hepcidin-modulating agents 
 
Hepcidin-targeted therapies may improve treatment options for patients suffering 
from iron disorders and eventually also AI. Although no specific hepcidin-
modulating therapies are available, several compounds are under development as 
hepcidin agonists or antagonists [62,71,72].  
Hepcidin agonists could be useful to prevent iron overload attributed to hepcidin 
deficiency, such as hereditary hemochromatosis, and especially く-thalassemias 
and other iron-loading anaemias, and possibly some acquired forms of 
nonhemochromatotic iron-overload diseases.  
Hepcidin antagonists, on the other hand, might be expected to benefit patients with 
diseases of hepcidin excess manifested as iron-restricted anaemia and systemic 
iron deficiency, such as iron-refractory iron-deficiency anaemia, anaemia of chronic 
diseases (rheumatic diseases, inflammatory bowel diseases, autoimmune 
diseases), chronic kidney disease, multiple myeloma and other cancers, obesity-
related iron deficiency, and cardiovascular disease. 
Preclinical studies to assess the efficacy of hepcidin-related therapies and large 
clinical trials addressing safety and long-term efficacy are needed to clarify the 
risks and benefits of hepcidin-targeted treatments.  
 
1.2 The anaemia of inflammation 
 
1.2.1 Definition of anaemia of inflammation 
 
The common features of AI [73] is a normocytic, normochromic anaemia, that can 
become microcytic and hypochromic as the disease progresses. Reticulocytosis is 
not usually observed. Low serum iron concentration is a hallmark of the clinical 
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presentation of AI and because it is present in iron deficiency, distinguish the two 
forms or the combination of both is of pivotal importance for the correct targeted 
therapy. The serum iron concentration and transferrin saturation are low, while 
macrophage iron stores remain replete.  
The variability in clinical expression of AI may be related to the duration or severity 
of the inflammation or to differential expression of various pro-inflammatory 
cytokines that direct the inflammatory response. 
Indeed, WKH YDULDWLRQ LQ WKH ³F\WRNLQH SURILOH´ DFURVV GLVHDVH VWDWHV may lead to 
variations in the mechanisms that restrict erythropoiesis or promote turnover of 
erythrocytes and therefore affect the presentation of AI. 
Table 1 shows blood serum iron parameters and they different pattern in the 
condition of AI, in the condition of iron deficiency and in the combined anaemia of 
iron deficiency and of inflammation. 
 
 
 
Table 1 ± blood serum iron parameters, hepcidin and C-RP patterns.  
(Modified from Lasocki et al. [2]) 
 
1.2.2 ³Tools´ for diagnosis of anaemia of inflammation 
 
Sensitive and specific clinical assays are essential for the diagnosis of AI and for 
the optimal clinical management.  
 
1.2.2.1 Whole blood count 
The World Health Organization defines anaemia as haemoglobin less than 13 g/dL 
in men less than 12 g/dL in women [74]. In AI, mean cell volume (MCV) and mean 
cell haemoglobin (MCH) are normal, but can drop as the disease persists. Red cell 
distribution width (RDW) indicates erythrocyte heterogeneity. A recent study 
suggests that increased RDW in heart failure is related to inflammatory 
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stress and impaired iron mobilization [75] indicating that it might also be useful in 
the diagnosis of AI. 
The presence of acute inflammation is often caused by occurrence of an infection 
and elevated neutrophils, monocytes, and platelets indicate inflammation. 
  
1.2.2.2 Serum inflammation markers 
The detection of C-reactive protein (C-RP) has improved and is routinely used in 
clinical management of inflammation, but remains a fairly nonspecific measure of 
inflammation. Recently the availability of pro-inflammatory cytokines kits for clinical 
use has been introduces into clinics, eventually helping to discriminate between the 
mechanisms that drive AI.  
 
1.2.2.3 Serum iron parameters 
Serum iron and transferrin (Tf) saturation are decreased in AI, indicating that the 
iron supply to the erythron is limited. Confirmation of sufficient iron stores can be 
difficult. Serum ferritin (sFt) is generally considered a marker of iron stores. 
Generally, when serum ferritin is below 30 ng/mL in an anaemic patient, iron 
deficiency can be diagnosed [1]. However, in many patients, a combination of iron 
deficiency and AI may exist. Serum ferritin is induced in response to inflammation. 
Thus, in the context of AI, it is a poor marker of available iron. Serum ferritin has 
been used in conjunction with the serum transferrin receptor (sTfR) to determine 
the sTfr/log sFt ratio. sTfR is produced when erythroid precursors have produced 
sufficient haemoglobin and shed the receptor. As iron availability to the erythron 
decreases, or as erythroid capacity increases, sTfR in the plasma increases. 
Despite iron restriction in the context of AI, sTfR is not elevated, but remains in the 
normal range due to downregulation by pro-inflammatory cytokines [76]. 
The sTfR/log sFt ratio can discriminate between iron-deficiency anaemia and AI. 
sTfR/log sFt >1.5 is most consistent with iron deficiency, but sTfR/log sFt <0.8 best 
defines iron deficiency with inflammation [77]. This diagnostic determination is 
currently limited in availability and is underutilized in clinical practice. 
 
1.2.2.4 Serum hepcidin 
Recently, several hepcidin assays have become available [64,70], but currently, 
there are no established standards or cut-offs for hepcidin based diagnoses [78]. 
Hepcidin levels must be interpreted in the context of the physiology of the 
individual. One might argue that an anaemic adult with hepcidin concentrations in 
the normal range has inappropriately elevated hepcidin, because it should be low 
in response to hypoxia. Several investigators have suggested methods to 
normalize hepcidin values based on other biomarkers such as sTfR, serum iron, or 
serum ferritin. However, because reliable methods for measures of hepcidin have 
only recently become available, more work must be done to assess hepcidin levels 
in various disease states before appropriate diagnostic guidelines can be 
developed. 
 
1.2.2.5 Establishment of algorithms to identify anaemia of inflammation and  
its differential diagnosis 
The aim of identify pure AI from combined disorders of iron-deficiency anaemia or 
other iron-restricted/iron-deficiency anaemias is to appropriate therapy and 
management. The algorithm would be helpful to indicate when iron 
supplementation or erythropoietin treatment may be beneficial but more importantly 
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to identify patients with a limited potential for response to these established 
therapies.  
For patient stratification, a scheme proposed by Weiss and Goodnough [1] was 
explored and expanded by Sasu et al. [79] and showed in figure 8. The Authors 
found that in their population, using either of these stratification schemes, hepcidin 
concentrations strongly correlated with AI. Less hepcidin elevation was seen in 
patients judged to have mixed anaemia (both inflammation and iron deficiency) 
despite the fact that these patients had detectable CRP levels. Many factors may 
explain this discrepancy, such as differences 
in the half-lives of CRP and hepcidin (the half-life of CRP is 19 h, whereas the half-
life of hepcidin may be much shorter [18]). Another intriguing explanation is the 
possibility that iron deficiency in these patients may be the counter-balancing of 
inflammation-induced hepcidin production [38].  
 
 
Figure 8 ± Proposed algorithms for anaemic patients (Hb less than 10 g/dL) 
stratification and categorization. (From Sasu et al. [79]) 
 
Van Santen et al. [80] proposed an algorithm to discriminate iron-deficiency 
anaemia in patients affected by rheumatoid arthritis (RA), hence with chronic 
inflammatory status. Their classification scheme precludes direct comparison of 
hepcidin or haemoglobin content parameters with any of the conventional 
parameters used for detection of true iron deficiency in RA patients. Hepcidin cut-
off s proposed have been validated in their cross sectional study, but the number of 
patients and the characteristics of patients are the main limitations. They concluded 
that rheumatologist should add hepcidin and reticulocytes-haemoglobin content 
parameters to the routinely clinical measurements in order to detect iron deficiency 
in RA patients with inflammation and anaemia (figure 9). 
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Figure 9 ± Proposed algorithms  by van Santen et al. [80]) 
IDA: iron deficiency anaemia; ACD: anaemia of chronic disease;  
C-RP: C-reactive protein; ESR: erythrocytes sedimentation rate; 
 Ret-HgB: reticulocyte haemoglobin content.  
 
1.3 The in vivo ³model´ of endotoxemia 
 
1.3.1 Patients hospitalized out of acute inflammatory diseases 
 
Since the first published investigation by Kemna et al [32] that showed the temporal 
associations between plasma cytokines, hepcidin levels, and serum iron 
parameters in 10 healthy human individuals after LPS injection, many ex-vivo 
experiments on cells cultures and animal models of induced acute infections by 
several pathogens have been described.  
To date, few studies have been conducted in the setting of acutely ill adult patients. 
Excluding injury, trauma or cancer patients, only van Eijk et al. [81] investigated the 
development of anaemia during acute systemic inflammation especially evoked by 
sepsis in the acute care units setting. They found that hepcidin-25 is increased 
during human sepsis and in septic patients the degree of inflammation, indicated 
by IL-6 levels and number of systemic inflammatory response syndrome (SIRS) 
criteria present, is associated with the elevated concentrations of hepcidin. 
Furthermore he showed that persistently increased levels of hepcidin-25 at day 2 
and 3 after admission are associated with a decrease in haemoglobin during 
hospitalization [81]. 
Other Authors recently [2,3,82] reviewed the issue of anaemia in critically ill 
patients in order to elucidate the linking between hepcidin-inflammation-anaemia 
and to propose clinical management based on pathogenetic mechanism. Human 
data concerning the effect of hepcidin release on the development of anaemia 
during acute inflammation in non-intensive care setting are still lacking. 
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2. STUDY AIM 
 
2.1 Rationale 
 
This study has been planned to verify in a clinical setting  the in vivo experimental 
endotoxemia model investigated in human healthy subjects, in animals or ex vivo in 
several cellular models [31,32,47-49]. 
The first investigation by Kemna et al in 2005 was conduct on 10 human healthy 
subjects injected with LPS, a more upstream inflammation activator, to study the 
temporal associations between plasma cytokines, hepcidin levels, and serum iron 
parameters. IL-6 was dramatically induced within 3 hours after injection, and 
urinary hepcidin peaked within 6 hours, followed by a significant decrease in serum 
iron[32]. These in vivo human results confirmed the importance of the IL-6±
hepcidin axis in the development of hypoferremia in inflammation and highlight the 
rapid responsiveness of this iron regulatory system.  
In 2008, Theurl et al. [47] showed that the small amounts of hepcidin produced by 
inflammatory monocytes/macrophages exerted autocrine regulation toward cellular 
iron metabolism. They found that monocyte hepcidin mRNA expression was 
significantly induced within 3 hours after stimulation with LPS or IL-6, and hepcidin 
mRNA expression was significantly higher in monocytes of patients with anaemia 
of chronic diseases (ACD) than in controls.  In ACD patients, monocyte hepcidin 
mRNA levels significantly correlated to serum IL-6 concentrations, and increased 
monocyte hepcidin mRNA levels were associated with decreased expression of the 
iron exporter ferroportin and iron retention in these cells. Transfection of monocytes 
with siRNA directed against hepcidin almost fully reversed this LPS-mediated 
effect, confirming the hepcidin autocrine activity on monocytes.  
In the following years few studies have been conducted in the setting of acutely ill 
patients admitted to intensive care units. In this setting, patients are affected by 
acute and severe inflammation and often by sepsis. These patients had very high 
levels of hepcidin at admission, and mostly normalized after three days of 
therapies. The 13% of patients needed at least one blood transfusion during the 
first 2 weeks of admission, not related to active bleeding [81].  
The present research project proposed to investigate the associations between 
different plasma cytokines, iron parameters, serum hepcidin, monocytes-derived 
hepcidin and the development of AI in the setting of acutely ill patients hospitalized 
for acute inflammatory diseases.  
 
2.2 Aims 
 
This study  aim is to develop effective strategies to detect and manage anaemia of 
inflammation (AI), through three main points: 
a) To evaluate hepcidin impact on anaemia in vivo through the model of acute 
inflammatory conditions in hospitalized patients 
b) To explore the molecular regulatory signalling network and timing of AI in 
circulating monocytes 
c) To identify AI-specific biomarkers, their diagnostic and prognostic useful 
and, eventually, targets for therapy. 
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Furthermore, the study  could evaluate the true impact of AI and the outcome of 
patients hospitalized for acute inflammatory conditions and the possible effects on 
hepcidin serum levels of some drugs frequently prescribed in the general 
population (e.g. statins, macrolides, heparins, et al.). 
 
2.3  strategy 
 
To analyse the time-course of inflammation, anaemia and hepcidin we  tested 
patients on first  and sixth day of admission. Although different from the 
experimental induced endotoxemia models, where it is well known the exact time of 
inflammation onset, this approach let us to standardized samples and findings, as 
well as the fact that all the analysis were conduct paired between 1st and 6th days 
for each patients. In a preliminary pilot study we tested different times and found 
that 6 days could be enough to capture the beginning of anaemia onset and 
LQIODPPDWLRQ UHFRYHU\ :H DOVR DGGUHVVHG WKLV ³RQH-ZHHN DSSURDFK´ LQ RUGHU WR
QRWH[FHVVLYHO\FDXVHSDWLHQWV¶EORRG ORVVE\YHQHSXQFWXUH ,QD IXUWKHUJURXSRI
patients, in addition to whole blood tests, biochemical and cytokines profiling, we 
investigated on first and eighth day of admission the monocytes-derived mRNA 
hepcidin. We chose an 8-days course approach out of hospital central laboratory 
reasons and to better evaluate recovery from inflammation. At admission, patients 
were characterized for site and type of infection, they were also stratified for 
severity of inflammatory responses and categorized for being anaemic or not-
anaemic. Comparisons between patients were conduct according to the mentioned 
clinical stratifications.  
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3. PATIENTS, MATERIALS AND METHODS 
 
3.1 Study setting and design 
 
This monocentric study has been conduct in Fondazione IRCCS Cà Granda 
Ospedale Maggiore Policlinico, a tertiary care university hospital in Milan and in its 
university research laboratories of the Università degli Studi of Milan, Italy. The 
study was approved by the Fondazione IRCCS Cà Granda Ethical Committee. 
Informed consent for obtaining additional peripheral blood samples for scientific 
purposes during routine blood drawing was obtained before the procedure from 
each subject in accordance with the Declaration of Helsinki. This study has been 
designed by G. Fabio, who is also the PI, and it has been registered in 
ClinicalTrial.gov (identification number NCT01589874). 
The study draw to consider each patient admitted to the Internal Medicine 
Department 1-A from Emergency Department because of acute inflammatory 
disease. The impact of inflammation on hepcidin production, iron metabolism and 
erythropoiesis have been investigated in vivo by evaluation on the first day of 
admission (T1) and on the sixth day of hospitalization (T6) of complete blood 
haematological test, serum inflammation markers, serum iron parameters, 
inflammation cytokines profiles, erythropoiesis signals and hepcidin concentration. 
In a subsets of patients the hepcidin mRNA production was investigated on 
SDWLHQWV¶EORRGSHULSKHUDOFLUFXODWLQJPRQRF\WHVLQRUGHUWREHWWHUFODULI\WKHLPSDFW
of monocytes activated hepcidin production in the setting of anaemia of acute 
inflammatory diseases. In this patients subgroup the investigation has been 
conduct on first day (T1) and on eighth day (T8) of admission. 
 
3.2 Patients 
 
All the consecutive adult patients hospitalized at the Internal Medicine Department 
1-A with diagnosis of acute inflammatory condition were enrolled if they satisfied 
the following inclusion criteria: serum C-Reactive Protein (C-RP) level > 3mg/dL 
and creatinine level < 2mg/dL (creatinine clearance >30%).  
Were excluded all the patients affected by any haematological diseases, cancer 
under chemotherapy, AIDS, liver cirrhosis, genetic hemocromatosis, 
immunosuppressive therapy, chronic erythropoietin therapy or blood transfusion in 
the past 30-days or during the enrolment time.  
The cause of inflammation were investigated and bleeding ruled out.  
The choice of diagnostic work up and therapy will be entirely dependent on the 
physician treating the patient and the enrolment in this study interfered in no case 
with the diagnostic and therapeutic management of the patient.  
All patients' data since admission until discharge were collected in an electronic 
database and analysed: 
- blood test analysis (collected by venepuncture at the same time for all 
analysis)  
- clinical parameters recorded at admission (arterial blood pressure, heart 
rate, body temperature, respiratory rate) 
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- SDWLHQWV¶ FRPRUELGLWLHV FDUGLRYDVFXODU DQG FHUHEURYDVFXODU GLVHDVHV
respiratory diseases, kidney disease, liver diseases, diabetes, neoplasms, 
immunosuppression, autoimmune diseases) 
- microbiological findings of samples collected at admission 
- instrumental examination for ruling out blood losses  
- diagnosis at discharge 
 
3.3 Laboratory measurements 
 
3.3.1 Biochemical assays 
 3DWLHQWV¶EORRGVDPSOHVZHUHGUDZQRn a routine basis and were measured using 
routine standard laboratory assays by automated analysers in the Hospital Central 
Laboratory according to ISO 9001 standard laboratory procedures. For each 
patient on the first day of admission (T1) was analysed: 
- complete routine haematology parameters: haemoglobin (Hb), blood red cells 
count (RBC), haematocrit (Hct), mean cell volume (MCV), mean cell haemoglobin 
(MHC), mean cell haemoglobin concentration (MCHC), white blood cells count 
:%&$UQHWK¶VOHXNRF\WHIormula (neutrophils (N), eosinophils (E), basophils (B), 
lymphocytes (L), monocytes (M)), platelets count (Plts) 
- serum inflammatory markers: C-reactive protein (C-RP), erythrocytes 
sedimentation rate (ESR), alpha-1-acid glycoprotein (AAG), haptoglobin (Hp), 
alpha-1-antitripsin (A1AT) 
- serum iron parameters: serum iron (Fe), ferritin, transferrin (Tf) 
- serum liver function tests: alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST), gamma-glutamyltransferase (GGT), bilirubinemia (total 
and direct), cholinesterase, albumin, alkaline phosphatase, coagulation parameters 
(PT, PTT) 
- serum kidney function tests: creatinine, uraemia, sodium 
- serum levels of folate and B12 vitamin 
- arterial blood gas analysis: pH, partial pressures of oxygen (PaO2), carbon 
dioxide (PaCO2), bicarbonate (HCO3-) and oxygen saturation (SaO2) 
 
For each patient on day sixth of admission (T6) was analysed: 
- complete routine haematology parameters 
- serum inflammatory markers 
- serum iron parameters 
- serum kidney function tests: creatinine, uraemia, sodium 
- oxygen saturation (SaO2) 
 
3.3.2 Serum cytokines profiling and serum erythropoietic signals 
 
Blood samples were obtained early in the morning after overnight fasting, on both 
first (T1) and sixth (T6) day of hospitalL]DWLRQ3DWLHQWV¶ZKROHEORRGZDVFROOHFWHG
into serum isolation tubes at the same time of routinely samples and centrifuged at 
least 2 hours later. SHUXPZDVVWRUHGDWí&LQDOLTXRWVWRDYRLGPXOWLSOHIUHH]H-
thaw cycles. Then samples were processed and the following analytics determined 
using commercially available enzyme-linked immunosorbent assay (ELISA) kits 
according to manufacturer's indications: 
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a) serum levels of soluble transferrin receptor (sTfR): BioVendor Laboratorni 
medicina Modrice- Czech Republic 
b) serum endogenous erythropoietin (EPO): IBL Hamburg-Germany 
c) growth differentiation factor-15 (GDF15): DuoSet ELISA R&D Systems, 
Minneapolis, MN USA 
d) serum cytokines:  
o Interleukin 1beta (IL-1ȕ): IBL Hamburg-Germany 
o Interleukin 6 (IL-6): Milenia Biotec GmbH Gieben-Germany 
o Interleukin 4 (IL-4): IBL Hamburg-Germany 
o Interleukin 10 (IL-10): IBL Hamburg-Germany 
o Interleukin 13 (IL-13): IBL Hamburg-Germany 
o Gamma-,QWHUIHURQȖ,)1,%/+DPEXUJ-Germany 
o Tumor Necrosis Factor-alpha (TNF-Į 0LOHQLD %LRWHF *PE+
Gieben-Germany 
 
3.3.3 Hepcidin and pro-hepcidin measurements 
 
3.3.3.1 Time-Of-Flight Mass Spectrometry quantitative hepcidin assays 
Serum hepcidin was measured by Surface-Enhanced Laser Desorption/Ionization 
Time-Of-Flight Mass Spectrometry (SELDI-TOF MS), using a synthetic hepcidin 
analogue (Hepdicin-24, Peptides International, Louisville, KY) as an internal 
standard, as previously described [83], with recent technical advances [84].  
 
 
 
Figure 10 ± SELDI-TOF MF profile of hepcidin-25 is indicated by arrows, The 
isoforms hepcidin-20 and hepcidin-24 are also indicated 
(Modified from Campostrini et al. [84]) 
 
3.3.3.2 Immunochemical hepcidin assays 
Of the currently available commercial immunochemical research kits for serum 
hepcidin, bioactive hepcidin kit of DRG Instruments (purchased October 2009; 
DRG Marburg-*HUPDQ\KDVEHHQXVHGWRWHVWVHUXPSDWLHQWV¶VDPSOHVDFFRUGLQJ
to manufacturer's indications.  
 
3.3.3.3 Immunochemical pro-hepcidin assays 
$FFRUGLQJ WR PDQXIDFWXUHU¶V LQGLFDWLRQV WKH FRPPHUFLDO NLW RI +HSFLGLQ
Prohormone ELISA (DRG Marburg-Germany) has been used to test serum 
SDWLHQWV¶VDPSOHV 
 
3.3.4 Interleukin-6 Receptor expression on monocytes  
 $OLTXRWV RI SDWLHQWV¶ ZKROH YHQRXV  EORRG FROOHFWHG LQWR ('7$-tubes were 
immediately addressed for IL-6 receptor quantification by flow cytometry. 
Expression of gp130 and CD126 on membrane of cells CD14+ were evaluated.  
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3.3.4.1 Monoclonal Antibodies 
The following monoclonal antibodies (mAbs) were used for detection of cell surface 
markers: 
 IL-5ĮFKDLQDQWL-human phycoerythrin (PE) labeled mAb CD126 (Becton 
Dickinson, San Jose, CA). 
 IL-5ȕ FKDLQ DQWL-human fluorescein-isothiocyanate (FITC) labeled mAb 
gp130 (Diaclone, Besancon, France). In the second protocol for T1-T8 
analysis, membrane gp130 expression was analysed with mAbs FITC-
labeled by Thermo Scientific (Waltham, MA, USA), obtained by the same 
cells of the previous one and with the same isotype: clone B-R3, mouse, 
isotype IgG2a. 
 Monocyte marker: Anti-human peridinin-chlorophyll-protein (PerCP) 
labeled CD14 (Becton Dickinson, San Jose, CA). 
 
3.3.4.2 Immunophenotyping 
6DPSOHVRIȝORIZKROHEORRGZHUHGLVWULEXWHGLQWRWHVWWXEHVDQGLQFXEDWHGZLWK
or without the selected monoclonal antibodies. Erythrocytes and platelets were 
selectively lysed by 2mL of BD FACSLysis (Becton Dickinson), then centrifuged at 
1500rpm for 10min at 4°C, one step wash with buffer Ca2+ and Mg2+ free 
phosphate buffered saline (PBS) and finally suspended in 0.5 ml cold phosphate 
buffered saline and promptly analysed. 
 
3.3.4.3 Flow cytometric analysis 
Three-color flow cytometric analysis was performed on on a FACSCAN 
cytofluorometer (Becton Dickinson, San Jose, CA). Data were acquired using 
CELL-Quest software (Becton Dickinson) on Mac OS 9.2. Analysis gate was set 
according to side-scatter (SSC-H) versus forward-scatter (FSC-H) acquiring 1 500 
total events in the gate of monocytes. CD126, gp130 and CD14+ values are 
expressed as percentage of positive cells, mean fluorescence intensity (MFI) and 
geometrical means have been used for comparison.  
 
3.3.5 Isolation of peripheral blood monocytes  
 
Whole blood from patients was sampled into EDTA-containing tubes on first day 
(T1) and eighth day (T8) of admission. Circulating monocytes CD14+ were 
negative isolated from whole blood samples by Dynal® 8QWRXFKHG +XPDQ
Monocytes 1HJDWLYH,VRODWLRQ.LW,QYLWURJHQ'\QDO® Invitrogen bead separations, 
Oslo, Norway). Isolation of peripheral blood mononuclear cells (PBMC) was carried 
out according to recommended sample preparation protocol (low platelets 
numbers).  
 
3.3.5.1 Reagents 
- 'HQVLW\*UDGLHQW/\PSKRSUHSIRU01&SUHSDUDWLRQ)LFROO-3DTXH 
- Depletion Dynabeads: Ca2+ and Mg2+ free phosphate buffered saline (PBS), pH  
  7.4, containing 0.1% bovine serum albumin (BSA) and 0.02% sodium azide 
(NaN3). 
- Dynal® Monocytes ,VRODWLRQ.LW,QYLWURJHQ'\QDO®, Oslo, Norway) Antibody Mix   
  containing mouse IgG antibodies for CD2, CD17, CD16 (specific for CD16a and    
  CD16b), CD19, CD56 and CD235a (Glycophorin A).  
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- %ORFNLQJ 5HDJHQW ,QYLWURJHQ '\QDO®, Oslo, Norway): aggregated gamma 
globulin in 0.9% NaCl. 
- QIAzol®. 
 
3.3.5.2 Methods 
Briefly, 14 ml EDTA-anticoagulation blood diluted 1:3 in isolation Ca2+ and Mg2+ 
free phosphate buffered saline (PBS) as underplayed over density gradient (Ficoll-
3DTXH FHQWULIXJHG DW USP IRU PLQ DW & 7KH 3%0& OD\HU ZDV
removed and washed twice with PBS supplemented with 0.1% BSA. Then, PBMC 
were incubated with the blocking reagent and antibody mix for 20min at 2-8°C, 
washed and incubated with beads (previously prepared) for 15min at 2-8°C. Hence 
the tube with PBMC and beads placed in the magnet for 3 min. Supernatants 
containing negative isolated CD14+ cells (untouched human monocytes) have 
been washed and aliquots of 500 x105 cell/µL stored at -80°C with QIAzol®.  
 
3.3.6 RNA isolation and quantitative real-time polymerase chain  
reaction (qRT-PCR) 
 
Determination of hepcidin (HAMP) mRNA expression in circulating monocytes 
CD14+ has been obtained after monocytes isolation (see above). Total cellular 
RNAs have been extracted from monocytes using a guanidinium-isothiocyanate-
phenol-chloroform-based procedure [85]. 2QH ȝO RI H[WUDFWHG 51$ KDV EHHQ
analysed for concentration and purity on a NanoDrop ND-1000 (Thermo Scientific) 
spectrophotometer. 
 
3.3.6.1 HAMP mRNA RT-PCR 
HAMP mRNA expression was evaluated by quantitative real-time PCR analysis 
using TaqMan technology. ȝJRIWRWDO51$ZDVUHYHUVHWUDQVFULEHGXVLQJWKH
high-capacity cDNA archive kit according to the manufacturer's protocol (Applied 
Biosystems, Life Technologies Corporation) on Eppendorf Mastercycler Gradient 
(Eppendorf, Hamburg, Germany). Real time PCR (RT-PCR) was performed on ABI 
PRISM 7500 Real Time PCR System.Both beta-actin has been used as internal 
FRQWURO JHQH 7KH DVVD\ ,' RI WKH WDUJHW DQG HQGRJHQRXV JHQHV ZDV ȕ-actin:  
Hs99999903_m1. Hepcidin (HAMP) used primers and probes are:  
Forward PrLPHU¶-GGCTCTGTTTTCCCACAACAG-¶ 
5HYHUVH 3ULPHU ¶-AGCCGCAGCAGAAAATGC-¶ +$03-MGB-FAM-SUREH ¶-
CAGCTGGATGCCCAT-¶(Cod 4331182 ± HAMP: HS00221783-m1) 
All experiments involving qRT-PCR were performed in duplicate, with two to three 
replicates each. The results of qRT-PCR were analyzed using SDS Software 
(Applied Biosystems, Life Technologies Corporation) that uses the 2íǻǻ&W method 
DFFRUGLQJ WR WKH IRUPXOD ǻǻ&W &WMUTí&WENDOí&WCTRLí&WENDO). The formula was 
modified in order to calculate the fold of change between T1 and T8 as follows: 
ǻǻ&W &WT1í&WENDOí&WT8í&WENDO) [86].  
 
3.4 Formulas 
 
3.4.1 Transferrin saturation 
 
The saturation of transferrin (ST%) with iron is an indicator of body iron stores, but 
also reflects the balance between reticuloendothelial iron release and bone marrow  
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uptake. Under normal conditions, about 30% of the transferrin (Tf) iron-binding 
sites are saturated. In humans, ST < 15% indicate iron deficiency, whereas ST > 
45% are consistent with iron overload [38].  
The saturation of transferrin with iron = Fe / (Tf x 1.25) x 100  
where Fe is serum iron levels (mg/dL), Tf is transferrin expressed in mg/dL. 
 
3.4.2 Ratio of soluble transferrin receptor to log ferritin 
 
A determination of the levels of sTfR can be helpful for differentiation between 
patients with anemia of chronic disease alone (with either normal or high ferritin 
levels and low levels of sTfR) and patients with anemia of chronic disease with 
accompanying iron deficiency (with low ferritin levels and high levels of sTfR). A 
ratio of less than 1 suggests anemia of chronic disease, whereas a ratio of more 
than 2 suggests absolute 
iron deficiency coexisting with anemia of chronic disease (see table 1).
 
Ratio of soluble transferrin receptor to log ferritin = sTfR / logferritin 
where sTfR is soluble transferrin receptor expressed in mcg/L and ferritin in mg/L  
 
3.5 Statistical Analysis 
 
Descriptive statistics were computed resorting to the Statistical Package for Social 
Sciences, version 17 (SPSS, Chicago, IL, USA). Data are expressed as mean ± 
standard deviation of the mean for continuous variables and as numbers 
(percentages) for categorical variables. Paired observations over time were tested 
with paired t-test or Wilcoxon matched-pairs test and unpaired observations with t-
test or a Mann-Whitney test if needed. As many of the continuous variables of 
interest, including cytokines, ferritin, GDF-15, and EPO, showed a non-Gaussian 
distribution, their values were log-transformed and plotted for the correlation 
analysis. Correlations between quantitative variables were assessed using 
3HDUVRQ
VFRHIILFLHQWRU6SHDUPDQ¶VRQHLIQHHGHG 
Analysis were firstly performed on whole patients population, then on comparison 
between subsets of patients according to differences in haemoglobin, inflammatory 
status or clinical stratification. In this thesis are shown data of patients who were: a) 
anaemic and not-anaemic on T1; b) with and without more than two SIRS criteria. 
Comparison have been performed between the two subgroups with unpaired tests 
and inside each subgroup with paired tests. 
In patients who were not-anaemic on T1, the discriminatory power of hepcidin, C-
RP and IL-6 variable to predict anaemia on T6 was assessed by calculating the 
area under (AUC) each receiver operating characteristic (ROC) curve [87]. To 
determine the accuracy of hepcidin in predicting anaemia on T6, we estimated the 
sensitivity, specificity, positive and negative predictive values, and likelihood ratios 
for each possible cut-off.  
The Youden¶V index, defined as (sensitivity + specificity) íZDVFDOFXODWHGDWHDFK
cut-off. The cut-off point which showed the highest Youden¶V index was considered 
the optimal cut-off value [88].  
The two tailed significance level of all the analyses was set at p < 0.05. 
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4. RESULTS 
 
Results are presented in detached paragraphs to better show any relation between 
hepcidin, haemoglobin, iron, erythropoiesis and inflammation. 
Firstly, analysis was performed on overall patients population (N=60) for baseline 
characteristics and comparison between T1 versus T6 findings. Then, main 
findings about links between hepcidin and inflammation, hepcidin and iron, 
hepcidin and erythropoiesis are shown (paragraph 4.1 to 4.5). 
Secondly, analysis was performed after that patients had been subdivided 
according to having sepsis (paragraph 4.6) and having anaemia (paragraph 4.7) at 
admission. Results on the compared analysis of patients with and without sepsis 
are briefly summarised. Findings on the comparison between patients anaemic and 
non-anaemic at admission are extensively detailed.  
The analysis focused on differences between subgroups features on T1 and on T6, 
and on the modification between T1 and T6 findings in the same subgroup. 
Corollary of this analysis was the identification of hepcidin cut-off level for 
prediction of anaemia occurrence on T6 (paragraph 4.8).  
On paragraph 4.9  findings from the subset of patients analysed on 1st and 8th day 
after admission and their peripheral blood isolated monocytes are described. 
Monocytes-derived hepcidin mRNA and its link with inflammation and iron 
parameters is showed. 
 
3DWLHQWV¶EDVHOLQHGHPRJUDSKLFVDQGLQIODPPDWRU\FDXVHV 
 
Eighty-three patients were eligible for this study. Nineteen were excluded after 
evaluation on T1 because of non responding to the inclusion criteria. Two patients 
were excluded because were found to have AI with true iron deficiency (sTfR/log 
ferritin ratio > 2 on admission findings).  
 
 
 
 
 
 
Figure 11 ± Selection of patients according to the algorithm modified from B.J. 
Sasu, et al., [81] 
 
Sixty subjects satisfied all the inclusion criteria: 32 females and 28 males, mean 
age was 70.6 years-old (SD ±18.3). Comorbidities more frequently observed were: 
cerebrovascular diseases (38.3%), lung diseases (30%), dementia (28.3%), 
83 patients 
19 patients 
60 patients 2 patients 
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diabetes (20%), cardiovascular diseases such as previous myocardial infarction 
(18.3%), previous congestive heart failure (11.7%), congestive heart failure at 
DGPLVVLRQ7DEOHGHWDLOVSDWLHQWV¶EDVHOLQHDQGFKDUDFWHULVWLFVDWKRVSLWDO
admission. 
 
BASELINE Mean SD
age at admission 70,62 18,30
lenght-of-hospital stay 14,17 8,83
referred days of inflammation before admission 6,12 7,70
N %
male 28 46,7
WHPSHUDWXUH&EHIRUHDGPLVVLRQ 29 55,8
hospitalization in the previous 6 months 14 23,3
iron therapy in the previous 30 days 2 3,4
alcohol abuse 3 5,1
immunocompetent 55 91,7
COMORBIDITIES Std. Deviation
autoimmune disease 3 5,0
cancer 9 15,0
methastatic cancer 2 5,6
cardiovascular diseases 31 51,7
only hypertension 21 35,0
past acute myocardial infarction 11 18,3
past congestive heart failure 7 11,7
congestive heasrt failure at admission 6 10,0
lung diseases 18 30,0
chronic liver diseases 4 6,7
chronic kidney diseases 6 10,0
diabetes 12 20,0
cerebrovascular diseases 23 38,3
dementia 17 28,3
 
 
Table 2 ± 3DWLHQWV¶EDVHOine characteristics and comorbidities 
 
All patients received antibiotic treatment within 24h from admission and before 
blood sample obtained. More representative causes of acute inflammation were 
(some causes overlap): pneumonia (45%), urinary tract infection (21.7%), 
exacerbation of COPD (11.7%), bacteraemia (10%), Cancer never treated (6.7%).  
More than two criteria of Systemic Inflammatory Response Syndrome (SIRS) were 
recognised in 55% (N=33) of subjects (table 3). Sepsis is diagnosed when a patient 
meets SIRS criteria and has a documented or suspected source of infection. 
Hence, 51.7% (N=31)  patients could be considered as having sepsis.  
 
 
 
Table 3 ± 3DWLHQWV¶FKDUDFWHUL]DWLRQDFFRUGLQJWR6,56FULWHULD 
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The main cause of acute inflammation was acute infections. Identified sites of 
infections were: lungs (63.3%), urinary tract (21.7%), skin (10%), gut (3.3%) as 
table 4 shows. Microbiologic investigations were performed in 58 of 60 patients. 
Aetiology was identified in 41.4% of cases: E. Coli accounts for 29.2%, 
Enterococcus spp. for 20.8%, Staphylococcus aureus for 12.5%. 
 
 
ACUTE INFLAMMATORY CAUSES N %
CANCER 4* 6,7
AUTOIMMUNE DISEASE 1 1,7
ACUTE INFECTIONS 57 95,0
SITE OF INFECTIONS° N %
blood culture positive infection 6 10,0
lungs 38 63,3
urinary tract 13 21,7
skin/bone 6 10,0
gut 2 3,3
* 2 overlap with infections
° two or more overlapping
 
 
Table 4 ± Causes of acute inflammation on admission 
 identified during hospitalization 
 
3DWLHQWV¶EDVHOLQHEORRGWHVWVDQGVHUXPF\WRNLQHV 
 
4.2.1 Whole blood tests, iron and inflammatory parameters 
 
On first day of hospitalisation (T1), haemoglobin (Hb) mean level was 12.4g/dL (SD 
±1.6). On T6, it was 11.9 g/dL (SD ±1.5; p<0.001). Also red blood cells count and 
haematocrit showed the same trend in the comparison between T1 and T6 (table 
5). On T6, 37 patients were found to be anaemic (overall mean Hb level 11.6 g/dl; 
SD ±1.3) according to WHO definition [74]. 
Considering inflammatory indices, C-Reactive protein (C-RP) mean serum levels 
on T1 were higher (13.3 mg/dl; SD ±1.3) than on T6 (5.3 mg/dl; SD ±5.0; 
p<0.0001). Alpha1-glicoprotein showed the same trend and erythrocytes 
sedimentation rate decreased  not significantly because usually it takes more than  
6-days to return to normal levels. The mean of white blood cells count on T1 was 
abnormal as it is in case of acute inflammation and returned to normal levels on T6 
(T1: 10.18 10*3cells/µL; SD ±4.40 versus T6: 8.69 10*3cells/µL; SD ±3.89; 
p=0.003). Also platelets count had the same T1-T6 trend (p<0.0001), as table 5 
shows. 
On T1, the mean serum iron levels of all the 60 patients were low (31.6mcg/dL; SD 
±19.2) and normalised on T6 (46mcg/dL; SD ±24.9; T6vsT1p<0.001). Elevated 
serum ferritin levels on T1, were still elevated on T6. All the serum iron parameters 
and inflammatory indices on T1 are showed on table 5. They were consistent with 
the definition of AI widely described in literature. 
During the 6-days course, none of the patients developed iron deficiency anaemia 
based on sTfR-ratio findings on T6 (T1 mean ratio 0.64; SD ±0.30; T6 mean ratio 
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0.53 SD ±0.33). In particular, the sTfR-ratio mean findings < 0.7 on T1 and on T6 
confirmed that any case of iron-deficiency have been excluded and confirmed that 
DOOSDWLHQWVKDG³SXUH´DFXWHLQIODPPDWLRQ 
 
 
 
VARIABLES on T 1 VARIABLES on T 6
COMPLETE BLOOD CELLS COUNT N Min. Max. Mean SD Min. Max. Mean SD p
UHGEORRGFHOOVȝ/ 60 3,09 5,3 4,26 0,58 2,93 5,34 4,10 0,61 <0,0001
mean cells volume (fL) 60 72 104 90,62 7,27 71 104 90,55 7,16 ns
haemoglobin (g/dL) 60 9,1 15,4 12,40 1,57 9,2 15,4 11,93 1,54 <0,0001
haematocrit (%) 60 29 48 38,43 4,50 29 46 36,88 4,15 <0,0001
mean cells haemoglobin 60 21 37 29,35 2,80 22 37 29,32 2,66 ns
mean cells haemoglobin concentration 60 29 39 32,37 1,48 28 38 32,35 1,60 ns
red cells distribution widith (RDW) 60 12 41 15,82 5,26 11 21 14,50 1,79
ZKLWHEORRGFHOOVȝ/ 60 4,25 25,5 10,18 4,40 3,97 18,3 8,69 3,89 0,003
neutrophils 58 49 90 73,55 10,63 32 85 64,41 13,38
eosinophils 58 0 10 1,43 2,04 0 41 4,42 6,12
basophils 58 0 1 0,09 0,28 0 1 0,17 0,38
lymphocytes 58 1 39 15,22 8,07 0 54 21,68 11,76
monocytes 58 2 19 9,48 3,38 3 16 9,80 2,51
SODWHOHWVȝ/ 58 92 677 238,28 99,78 127 786 296,23 113,47 <0,0001
UHWLFXORF\WHVÅ  55 0,02 4,6 1,23 0,70 0,03 5,2 1,21 0,80 ns
UHWLFXORF\WHVȝ/ 55 0,01 1,05 0,09 0,17 0,01 1,11 0,08 0,17
SERUM IRON PARAMETERS
VHUXPLURQȝJG/ 60 8 137 31,60 19,22 11 137 46,47 25,23 <0,0001
transferrin (mg/dL) 59 108 286 187,02 40,94 87 272 183,22 41,70
transferrin saturation (%) 59 3,54 35,47 12,26 6,46 3,89 44,92 17,86 8,79 <0,0001
ferritin (ng/dL) 60 48 3957 465,12 633,37 42 5917 416,67 763,65 ns
INFLAMMATORY INDICES
erythrocytes sedimentation rate (mm/h) 55 12 131 63,22 30,34 15 122 64,71 32,68 ns
C-reactive protein (mg/dL) 60 2 33,6 13,28 7,44 0 22,7 5,28 5,04 <0,0001
alpha1-acid glicoprotein (mg/dL) 58 85 370 171,95 50,68 83 266 164,37 47,91 0,041
alpha1-antitripsin (mg/dL) 60 148 383 222,65 56,25 125 308 215,95 43,73 ns
aptoglobin (mg/dL) 60 72 746 317,83 129,32 72 567 324,44 115,93 ns
other indices
albumin (g/dL) 60 2,3 4,5 3,47 0,51 2,1 4,8 3,37 0,59
serum creatinin (mg/dL) 60 0,2 1,8 0,95 0,31 0,4 1,5 0,82 0,24
 
 
Table 5 ± Complete blood cells count, serum iron parameters and serum 
inflammation markers on T1 and T6 
 
4.2.2 Serum cytokines profiling 
 
Table 6 shows serum cytokines profiling on T1 and T6 and comparison. Among 
pro-inflammatory cytokines, IL-6 was the highest on T1 (69.58 pg/mL; SD ±60.28), 
as expected in acute inflammation, and significantly decreased on T6 (45.93 
pg/mL; SD ±30.07; p=0.002), after that antibiotics treatment solved infection. IL-1, 
alpha-TNF and IL- GLGQ¶W VKRZ VLJQLILFDQW FKDQJHV EHWZHHQ 7 DQG 7 LQ WKH
overall patients. Anti-LQIODPPDWRU\F\WRNLQHV OHYHOVGLGQ¶WFKDQJHEHWZHHQ7DQG
T6, except than mean levels of gamma-IFN that decreased on T6 (p=0.028). This 
findings seems to correlate better to erythropoietin increase than to IL6 decrease. 
Gamma-IFN, as described elsewhere [89], seems to have a negative role in 
regulating erythropoietin activity, indeed erythropoietin had higher levels on T6 
(31.04 pg/mL; SD ±19.78) than on T1 (25.16 pg/mL; SD ±21.00; p=0.017).  
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CYTOKINES VARIABLES on T 1 VARIABLES on T 6
Pro-inflammatory N Min. Max. Mean SD Min. Max. Mean SD p
IL-1 (pg/mL) 29 4,90 6,11 5,30 0,29 4,93 5,80 5,19 0,21 ns
IL-6 (pg/mL) 60 16,87 424,70 69,58 60,28 15,69 172,90 45,93 30,07 0,002
IL-13 (pg/mL) 60 0,03 19,30 2,96 3,69 0,00 40,20 3,98 7,54 ns
alpha-TNF (pg/mL) 60 3,60 75,80 14,53 13,44 3,60 238,80 14,58 29,73 ns
Anti-inflammatory
IL-4 (pg/mL) 60 2,10 64,20 9,42 8,52 2,10 72,80 11,58 11,18 0,046
IL-10 (pg/mL) 60 1,50 38,30 7,25 6,48 1,50 50,40 5,91 6,52 ns
gamma-IFN (pg/mL) 60 0,90 55,00 5,06 9,81 0,90 26,80 2,70 3,65 0,028
erythropoietic modulatories
Erythropoietin (pg/mL) 60 1,20 92,30 25,16 21,00 0,30 90,90 31,04 19,78 0,017
GDF-15 (pg/mL) 31 290,00 16999,00 3818,18 3431,28 126,00 21283,00 3692,18 4186,34 ns
Hepcidins
serum pro-Hepcidin (nM/L) 29 88,00 398,00 223,59 77,85 95,00 409,00 225,41 78,55 ns
serum 25-Hepcidin  (nM/L) 59 0,81 58,28 23,04 15,46 0,55 46,39 12,35 9,84 <0,0001
 
 
 
Table 6 ± Serum cytokines profiling on T1 and T6,  
erythropoietic factors and serum hepcidin levels 
 
 
4.2.3 Hepcidin and pro-Hepcidin  
 
4.2.3.1 Hepcidin 
The quantification of hepcidin has been found to be complicated by its tendency to 
aggregate [90] and to stick to laboratory plastics, necessitating implementation of 
robust laboratory procedures. Reliable assays to measure hepcidin in blood and 
urine by use of immunochemical and mass spectrometry methods have been 
developed.  
We found that serum 25-hepcidin mean levels in all 60 patients measured by 
SELDI-TOF MS on T1 (23.04 nM/L; SD ±15.46) were higher than on T6 (12.35 
nM/L; SD ±9.84; p<0.0001) and the comparison between T1 and T6 serum values 
were significantly different (p<0.0001). The 25-hepcidin serum mean levels on both 
T1 and T6 are over the cut-off established by van Santen et al. in RA patients with  
anaemia of chronic inflammation [80]. Moreover we found that our results are very 
close with the findings obtained by van Eijk et al. in patients with sepsis [81], even 
though we did not found correlation between the number of SIRS criteria met and 
the hepcidin levels (see paragraph 4.6). 
 
 
4.2.3.2 Reference interval for serum 25-hepcidin 
The hepcidin values obtained in the patients on T1 could be considered high, if 
compared with a group of 54 healthy individuals (61.1% males) with rigorous 
definition of normal iron status [83,91], whose serum hepcidin-25 mean levels was 
4.20 nM/L (range 3.53-5.00) measured with MS in the same laboratory performing 
this study (see chapter 3.3.3.1, Campostrini et al [84]). However, considerable 
inter-individual variation in hepcidin concentrations have been found also in healthy 
controls and, like other hormones, it should be interpreted in the context of other 
indices of iron metabolism. To date, differences in hepcidin concentrations between 
the sexes have not been consistently found [70]. 
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4.2.3.3 Comparison between serum 25-hepcidin detection by SELDI-TOF MS 
versus EIA methods 
Measurement by bioactive hepcidin kit of DRG Instruments (purchased October 
2009) on a sample of 30 patients also showed that serum T1 mean levels (8.40 
ng/mL; SD ±2.16) were higher than T6 mean levels (5.53 ng/mL; SD ±2.55; 
p<0.0001). However, we found negative correlation between serum hepcidin 
values obtained by MS and by EIA methods on T1 (r = -0,475: p=0.007) and there 
was no correlation at all between the values on T6 (R = -0.210, p=0.265) and the 
inverted correlation trend was confirmed (see figure 11). 
Moreover, no significant correlations were found for both serum hepcidin levels on 
T1 and on T6 detected with EIA and the respective serum levels of IL-6. 
Furthermore on T1 there was an inverted correlation that is the opposite of the 
findings on serum 25-hepcidin detected with SELDI-TOF MS. Indeed, a positive 
correlation between hepcidin and IL-6 should be found, as previously described 
(see chapter 1), and it was found only with the serum 25-hepcidin measured with 
MS (see next paragraphs). Because of the discrepancy between the two dosages 
and the lack in correlation with IL-6 serum levels we abandoned EIA method and 
considered only hepcidin-25 serum levels obtained by SELDI-TOF MS. 
 
 
 
 
 
 
Figure 11 ± Correlation between serum 25-hepcidin  
detected by SELDI-TOF MS (Y axis) and EIA (X axis). 
 
Other investigators found similar discrepancy in the comparison of different 
commercial immunochemical research kits for serum hepcidin methods to the DRG 
Instruments  EIA [70].  
One cause could be the difficulty in generating specific anti-hepcidin antibodies 
because of the small and compact structure of hepcidin, which leaves scarce 
antigenic epitopes (figure 1), associated with the high degree of conservation  of 
hepcidin among a wide range of species, which diminishes the elicitation of an 
immune response. Recently, substantial progress has been made in the 
methodologies in order to obtain reliable hepcidin assays, also with ELISA methods 
[70,92].   
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4.2.3.4 Pro-hepcidin 
Pro-hepcidin mean serum levels had no change on T1 and on T6 (sample of 30 
patients). Pro-hepcidin serum leYHOVZHUHXQUHODWHGWRSDWLHQWV¶KDHPRJORELQLURQ
or inflammatory status and cytokines patterns.  
Because of these results, the relationship between hepcidin-25 serum 
concentration measured using a SELDI-TOF MS method and pro-hepcidin 
measured by the DRG ELISA was explored. Only correlation between on T1 was 
significant (r = 0.415, p=0.028). No other correlations were observed between their 
FRQFHQWUDWLRQVLQDJUHHPHQWZLWKDQDO\VLVLQRWKHUSDWLHQWV¶SRSXODWLRQV 
 
  
 
Figure 12 ± Correlation between serum 25-hepcidin (detected by MS) 
 and serum pro-hepcidin (EIA). 
 
Sasu et al. [79] largely investigated the causes of these incongruent results 
between serum levels of pro-hepcidin measured by DRG kit and hepcidin-25 serum 
levels. They hypothesised that pro-hepcidin was degraded or masked in the 
presence of serum. An experiment using antibody against mature hepcidin capable 
of detecting both hepcidin and pro-hepcidin by Western blot revealed that the 
presence of 10% of serum led to degradation of pro-hepcidin to form hepcidin. The 
Authors suggest that the unstable nature of pro-hepcidin in the serum could be 
probably due to the enzymatic activity of a serum protein that has not yet been 
identified. Pro-hepcidin proved to be an unstable analyte in serum, then storage 
and handling of samples could cause significant variability in its analysis. 
Therefore, also out of the poor results in the first sample of 30 patients, we decided 
not to test it further in this study. 
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4.3 Serum hepcidin and serum cytokines  
 
IL-6 was highest on T1 (69.58 pg/ml; SD ±60.28), and decreased on T6 (45.93 
pg/ml; SD ±30.07; p=0.002). A similar pattern was observed for hepcidin levels, 
being highest on T1 (23.04 nM/L; SD ±15.46) and declining to 12.35 nM/L (SD 
±9.84; p<0.0001) on T6. IL-6 levels correlated significantly with hepcidin levels on 
T1 and on T6 (r = 0.26, p = 0.05; r = 0.45, p< 0.0001, respectively).  
Figure 13 shows the plots of the relationships on T1 between hepcidin-25 serum 
levels and IL-6 (upper left), IL-10 (upper right), alpha-TNF (lower left) and gamma-
IFN (lower right). Correlation trend line and R-square values are also showed. As 
previously described in cellular model ex vivo [28], hepcidin-25 serum levels 
increase according to IL-6 serum levels increase but not with alpha-TNF and 
gamma-IFN variations. 
 
 
  
 
 
Figure 13 ± On T1 correlation between serum 25-hepcidin 
 and IL-6, IL-10, alpha-TNF and gamma-TNF 
 
Figure 14 shows the correlation plots on T6 between hepcidin-25 serum levels and 
IL-6 (upper left), IL-10 (upper right), alpha-TNF (lower left) and gamma-IFN (lower 
right). On both T1 and T6 correlation trend between these cytokines and hepcidin 
is the same of the ones observed on T1. 
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Figure 14 ± On T6 correlation between serum 25-hepcidin and IL-6, 
IL-10, alpha-TNF and gamma-TNF 
 
4.4 Serum hepcidin, haemoglobin, iron, erythropoiesis and 
inflammation 
 
4.4.1 Hepcidin, haemoglobin and ferritin  
 
In the overall 60 patients, the relationship between serum hepcidin-25 levels and 
haemoglobin levels on both T1 and T6 showed that the higher was the hepcidin the 
lowest the haemoglobin, even though there was no statistical significance because 
of the dispersion of the data (figure 15, upper plots). We investigated also if the 
amount of hepcidin on T1, when the inflammation was higher, had an influence on 
haemoglobin levels on T6 (figure 15, lower left). We found that the correlation was 
markedly negative, but not statistical significant (r= -0.256; p=0.051). However, 
hepcidin levels on T1 did not correlate with the percentage of decrease of 
haemoglobin in the six-day course of observation (r = -0.079; p=0.553). 
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Figure 15 ± Correlation between serum 25-hepcidin  
and haemoglobin levels on T1 and T6 
 
As expected, on both T1 and T6 hepcidin serum levels positive correlated with 
ferritin serum levels (figure 16), especially on T6 (correlation with serum log ferritin 
on T6 r=0.522; p<0.001). Serum ferritin is primarily produced by macrophages [94] 
and it could be hypotised that the persistence of inflammation increased 
macrophages activation and iron stores (under hepcidin influence), hence higher 
ferritin levels associated with high hepcidin levels were more evident on T6 
evaluation. 
 
 
 
Figure 16 ± Correlation between serum 25-hepcidin and serum ferritin (log)  
on T1 and on T6 
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4.4.2 Hepcidin, haemoglobin and erythropoietin 
 
Erythropoietin (EPO) had an inverse correlation with haemoglobin levels on both 
T1 and T6 (figure 17, plots C and D), and the negative correlation was more 
significant between EPO levels on T1 with haemoglobin levels on T6 (r=-0.532; 
p<0.0001) showed in figure 17 (plot E). The relationship between EPO and Hb 
showed that patients anaemic on T1 and still anaemic on T6 manteined high EPO 
OHYHOV (YHQWKRXJK WKHVH SDWLHQWV¶ +E OHYHOV ZHUH VWLOO ORZ RQ 7, it may be 
hypothesised that they had an increased erythropoietic activity out of the positive 
correlations between: EPO and percentage of retyculocytes on both T1 (r=0,489; 
p<0.001) and T6 (r=0.367; p=0.004); EPO on T1 and percentage of retyculocytes 
on T6 (r=0.539; p<0.0001); EPO and RDW on T6 (r=0.304; p=0.018). Also sTfR on 
T6 had positive correlation with EPO on T6 (r=0.263; p=0.042), as well as EPO and  
alpha1-antitripsin on T6 (r=0.386; p=0.002), confirming this hypothesis.  
No significant correlations were found between EPO and hepcidin, even though on 
T1, high values of EPO have been observed in patients with high values of 
hepcidin, that could be explained as a suppressor signal as high values of EPO 
persist on T6 while hepcidin values becamed lower (figure 17, plots A and B). 
  
 
 
Figure 17 ± Correlation between serum 25-hepcidin, haemoglobin  
and serum EPO (log) on T1 and on T6 
A B 
C D 
E 
F 
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4.4.3 Hepcidin, erythropoietin and GDF-15 
 
The role of GDF-15 as possible inhibitor of hepcidin in patients without 
haematological diseases has been debated [95]. The relationships between their 
serum levels were also explored. We found a positive correlation between hepcidin 
values on both T1 and T6 (figure 18, upper plots). Also EPO and GDF-15 
correlated positively both on T1 and T6. Data by Ramirez et al in 2009 [96] 
supported the concept that apoptotic erythroblasts produce GDF15, and that 
GDF15 contributes to extra-erythroid tissue iron loading due to ineffective 
erythropoiesis. Our results suggest that GDF15 is a marker of ineffective 
erythropoiesis which occur also in the AI of acute ill patients setting. 
Kanda et al. in 2008 performed an in vivo physiological study of the relationship 
between GDF15, serum hepcidin, and erythropoiesis in the clinical setting of stem 
cell transplantation (SCT) [97]. After SCT, after recovery, serum hepcidin levels 
showed a significant inverse correlation with markers of erythropoietic activity, such 
as the sTfR and the reticulocyte counts, but not GDF15 levels. 
2XU SDWLHQWV¶ ERQH PDrrow was under erythropoietic pressure (not yet effective), 
therefore, our findings seems to corroborate the hypothesis that the persistence of 
GDF-15 high levels contributes to hepcidin suppression in the pathological setting 
of ineffective erythropoiesis as originally proposed [59]. 
 
 
 
 
Figure 18 ± Correlation between serum 25-hepcidin, GDF-15 (log) and serum EPO 
(log) on T1 and on T6 
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4.4.4 Hepcidin and serum inflammatory markers 
 
Correlation between hepcidin serum levels was strengthened on T6 than on T1 
(figure 19). Correlation between C-RP and hepcidin on T6 were high significant 
(r=0.495; p<0.0001), as expected. C-RP levels on T6 dropt down to low levels, 
while the other three inflammation markers (ESR, alpha-1 acid glycoprotein, 
haptoglobin) remained high with a width distribution, although the positive 
correlation trend was maintained.   
 
 
 
 
 
 
Figure 19 ± Correlation between serum 25-hepcidin  
and serum inflammation markers on T1 and on T6 
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3DWLHQWV¶RXWFRPHVRQ7 
Considering the outcome on T6 of the patients population analysed in this study, 
we found that: 
a- 26 patients anaemic on T1 were still anaemic on T6 (group A) 
b- 20 patients not anaemic on T1 were still not anaemic on T6 (group B) 
c- 11 patients not anaemic on T1 became anaemic on T6 (group C) 
d- 3 patients on T1 improved and recovered anaemia on T6 (group D) 
No patients died during the six-days course of the study nor during all the hospital 
long-of-stay. 
Considering the demographic an clinical characteristics on admission of the 
patients in group A, their mean age was 75.9 years  (SD ±11.3), they met a median 
of 2  SIRS criteria. The underlying causes of acute inflammation recognised during 
hospitalization were septicaemia (N=2), pneumonia (N=15), urinary tract infection 
(N=7), cancer new diagnosed (N=3) and autoimmune disease new diagnosed 
(N=1). 
The group B findings were slightly different. Mean age 61.5 years old (SD ±24.4), 
the median of SIRS criteria met was 1, the underlying causes of acute inflammation 
recognised during hospitalization were septicaemia (N=1), pneumonia (N=6), 
urinary tract infection (N=2), other unknown cause of acute infection (solved on 
discharge).  
The group C patients mean age was 76.3 (SD ±8.2). SIRS mean criteria met was 
1.6. Ten patients were affected by acute infections: pneumonia and septicaemia 
(N=1), pneumonia (N=2), pneumonia and urinary tract infection (N=3), urinary tract 
infection (N=1), gut infection (N=2). One patients was diagnosed for pleural 
effusion without bacterial infection nor cancer evidence, although he had a 
previous history of prostatic cancer.  
The latter group had mild acute inflammatory diseases, according to the number of 
SIRS criteria met. 
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4.6 Patients and acute inflammation 
Considering features at admission, patients were stratified according to SIRS 
criteria and causes of inflammation. Patients who met at least 2 SIRS criteria with 
an identified cause or site of infection were diagnosed for sepsis. 
 
Among the 60 patients enrolled, 31 patients were found to have sepsis. The 
comparison of patients with and without sepsis showed significant differences just 
for IL-6, C-RP, white blood cells count and RDW. Haemoglobin mean levels did not 
differed nor on T1 (sepsis: 12.2 g/dL; SD ±1.5; non-sepsis: 12.6 g/dL; SD ±1.6) 
neither on T6 (sepsis: 11.7 g/dL; SD ±1.6; non-sepsis: 12.2 g/dL; SD ±1.5). Also 
hepcidin mean levels on T1 were not different between the two groups (sepsis: 
23.0 nM/L; SD ±15.9; non-sepsis: 22.8 nM/L; SD ±16.5). Although differences in 
the intensity of the inflammatory response, and consequently in SIRS criteria, the 
two subgroups did not show significant differences for any other parameters. These 
findings corroborate the fact that we investigated a homogeneous population, 
restrictively selected at admission. Indeed all the patients except 5 had an acute 
infection underlying their acute inflammation; hence the similarity between the two 
subgroups could be explained out of the bias on admission selection.  
 
Unlike Eijk et al. [81], we did not found any clear relationship between the mean 
levels of serum hepcidin and the number of SIRS criteria nor in the whole patients 
population, neither in the sepsis subgroups (figure 20 below). Probably, the low 
number of patients in the sepsis subgroup (and especially with more than 3 criteria) 
could be one of the explanations of the lack of increasing hepcidin levels according 
to SIRS criteria met.  
 
 
  
 
Figure 20 ± Hepcidin levels distribution according to SIRS criteria met in the whole 
patients population (on the left) and in the sepsis subgroups (on the right) 
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4.7 Acute inflammation and anaemia 
 
4.7.1 Anaemic and not-anaemic patients at admission 
 
On T6, 37 patients were found to be anaemic (overall mean Hb level 11.6 g/dl; SD 
±1.3) according to the WHO criteria (HEJG/ IRU IHPDOHDQG IRUPDOH
[74] . Analysing data in order to found similarities and subsets of patients, we firstly 
focused on Hb levels.  
On the basis of Hb levels on T1, two groups of 29 and 31 patients each (named 
³DQDHPLF´ DQG ³QRW-anaemLF´ UHVSHFWLYHO\ KDYH EHHQ LGHQWLILHG 7KH JURXS RI
SDWLHQWV GHILQHG DV ³DQDHPLF´ RQ 7 +E  JG/ 6'  GLG QRW KDYH
changes in Hb mean levels on T6 (Hb 10.9 g/dL; SD ±1.14). In the 31 patients 
GHILQHGDV ³QRW-DQDHPLF´+EPHDQ OHYHORQ7ZDV.6 g/dL (SD ±0.94) and a 
0.7mg/dL decreased on T6 was observed (p<0.0001). Hepcidin mean level (as well 
as IL-6 levels) was higher in the anaemic group on T1 than in the not anaemic, and 
in both groups it decreases on T6.  
 
ON  T1
COMPLETE BLOOD CELLS COUNT N Minimum Maximum Mean SD N Minimum Maximum Mean SD p
red blood cells (10*6/ȝL) 29 3,09 4,9 3,88 0,45 31 3,65 5,3 4,62 0,44 <0,001
mean cells volume (fL) 29 72 104 91,07 8,69 31 79 102 90,19 5,74 ns
haemoglobin (g/dL) 29 9,1 12,7 11,11 0,95 31 12 15,4 13,62 0,94 <0,001
haematocrit (%) 29 29 39 34,93 2,66 31 36 48 41,71 3,20 <0,001
mean cells haemoglobin 29 21 37 29,17 3,37 31 26 34 29,52 2,17 ns
mean cells haemoglobin concentration 29 29 39 31,93 1,77 31 30 34 32,77 1,02 0,026
red cells distribution widith (RDW) 29 12 36 16,38 5,55 31 12 41 15,29 5,01 ns
white blood cells (10*3/ȝL) 29 5,77 19,9 10,40 4,14 31 4,25 25,5 9,98 4,70 ns
platelets (10*3/ȝL) 27 130 677 276,41 117,66 31 92 378 205,06 66,87 0,005
reticulocytes (Å) 25 0,22 4,6 1,40 0,87 30 0,02 1,82 1,09 0,48 ns
SERUM IRON PARAMETERS
serum iron (ȝg/dL) 29 8 73 26,83 13,95 31 12 137 36,06 22,40 ns
transferrin saturation (%) 28 3,54 28,25 11,64 5,97 31 4,79 35,47 12,81 6,92 ns
ferritin (ng/dL) 29 48 3957 582,83 856,33 31 79 1246 355,00 280,36 ns
INFLAMMATORY INDICES
erythrocytes sedimentation rate (mm/h) 26 18 131 79,00 29,61 29 12 90 49,07 23,54 <0,001
C-reactive protein (mg/dL) 29 2,3 33,6 15,07 7,64 31 2 30,3 11,61 6,96 ns
alpha1-acid glicoprotein (mg/dL) 28 106 294 184,18 42,01 30 85 370 160,53 55,92 ns
alpha1-antitripsin (mg/dL) 29 149 383 235,69 54,42 31 148 371 210,45 56,03 ns
aptoglobin (mg/dL) 29 91 746 347,31 131,03 31 72 618 290,26 123,46 ns
NOT ANAEMIC on T 1ANAEMIC on T 1
 
 
Table 7 ± Comparison between anaemic and not-DQDPHLFSDWLHQWV¶ILQGLQJVRQ7 
 
As shown on table 7, on T1 the two groups were not different for serum iron 
parameters nor for serum inflammation markers, except ESR, which was higher in 
the anaemic group. On the contrary on T6 (table 8), the two groups had slight 
differences for both iron and inflammation parameters. In particular, anaemic 
patients were found to have still higher long-standing inflammation markers (as 
ESR and alpha1-acid glycoprotein) while C-RP tapered down, meaning that other 
mechanisms concurred to the maintenance of inflammation.  
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ON  T6
COMPLETE BLOOD CELLS COUNT N Minimum Maximum Mean SD N Minimum Maximum Mean SD p
red blood cells (10*6/ȝL) 29 2,93 5,29 3,81 0,53 31 3,18 5,34 4,38 0,55 <0,001
mean cells volume (fL) 29 71 104 91,07 8,55 31 80 101 90,06 5,66 ns
haemoglobin (g/dL) 29 9,2 13,6 10,88 1,14 31 10,4 15,4 12,90 1,18 <0,001
haematocrit (%) 29 29 41 34,41 3,29 31 31 46 39,19 3,53 <0,001
mean cells haemoglobin 29 22 33 28,83 2,73 31 26 37 29,77 2,57 ns
mean cells haemoglobin concentration 29 28 34 31,62 1,27 31 31 38 33,03 1,60 <0,001
red cells distribution widith (RDW) 29 12 21 14,90 1,93 31 11 18 14,13 1,59 ns
white blood cells (10*3/ȝL) 29 5,14 18,21 9,06 3,83 31 3,97 18,3 8,33 3,97 ns
platelets (10*3/ȝL) 29 161 786 315,38 115,07 31 127 612 278,32 110,80 ns
reticulocytes (Å) 29 0,04 5,2 1,43 1,02 31 0,03 1,92 1,01 0,44 0,049
SERUM IRON PARAMETERS
serum iron (ȝg/dL) 29 11 81 37,28 18,33 31 17 137 55,06 27,93 0,005
transferrin saturation (%) 29 3,89 31,52 15,35 7,32 31 5,78 44,92 20,20 9,50 0,031
ferritin (ng/dL) 29 42 5917 508,93 1068,05 31 50 1169 330,35 257,43 ns
INFLAMMATORY INDICES
erythrocytes sedimentation rate (mm/h) 27 18 122 76,26 30,19 29 15 106 53,97 31,68 0,009
C-reactive protein (mg/dL) 29 0,6 22,7 6,43 5,89 31 0 13 4,20 3,89 ns
alpha1-acid glicoprotein (mg/dL) 29 112 262 177,79 41,39 31 83 266 151,81 50,77 0,035
alpha1-antitripsin (mg/dL) 29 150 305 223,62 37,07 31 125 308 208,77 48,67 ns
aptoglobin (mg/dL) 28 97 564 346,50 107,21 31 72 567 304,52 121,55 ns
ANAEMIC on T 1 NOT ANAEMIC on T 1
 
 
Table 8 ± Comparison between anaemic and not-DQDHPLFSDWLHQWV¶ILQGLQJVRQ7 
 
Cytokines profiling of the two groups on T1 and T6 is showed and compared in 
table 9 and 10. No differences between the two groups in the comparison of pro 
and anti-inflammatory cytokines on both T1 and T2 were found. However, EPO 
was high on T1 in the anaemic group and still remained high on T6. No differences 
were observed in the comparison of hepcidin mean serum levels. 
 
CYTOKINES  ON  T1
Pro-inflammatory N Minimum Maximum Mean SD N Minimum Maximum Mean SD p
IL-6 (pg/mL) 29 29,50 424,70 76,75 73,17 31 16,87 193,50 62,88 45,32 ns
IL-13 (pg/mL) 29 0,40 17,40 2,89 3,54 31 0,03 19,30 3,03 3,88 ns
alpha-TNF (pg/mL) 29 4,00 58,90 12,54 9,84 31 3,60 75,80 16,38 16,05 ns
Anti-inflammatory
IL-4 (pg/mL) 29 3,40 64,20 10,52 11,18 31 2,10 23,70 8,39 4,89 ns
IL-10 (pg/mL) 29 2,20 31,40 7,22 5,96 31 1,50 38,30 7,26 7,03 ns
gamma-IFN (pg/mL) 29 0,90 45,90 4,03 8,55 31 0,90 55,00 6,02 10,92 ns
erythropoietic modulatories
Erythropoietin (pg/mL) 29 5,40 92,30 33,18 25,87 31 1,20 49,00 17,65 11,07 0,005
GDF-15 (pg/mL) 29 445,00 16999,00 5186,35 3729,53 31 290,00 8636,00 2538,29 2838,00 0,002
Hepcidins
serum 25-Hepcidin  (nM/L) 28 3,17 58,28 24,48 16,75 31 0,81 46,48 21,74 14,35 ns
NOT ANAEMIC on T 1ANAEMIC on T 1
 
 
Table 9 ± Comparison between anaemic and not-DQDPHLFSDWLHQWV¶ 
cytokines profiling on T1 
 
CYTOKINES  ON  T6
Pro-inflammatory N Minimum Maximum Mean SD N Minimum Maximum Mean SD p
IL-6 (pg/mL) 29 16,48 172,90 51,07 33,31 31 15,69 108,70 41,13 26,33 ns
IL-13 (pg/mL) 29 0,00 33,20 2,90 6,53 31 0,00 40,20 4,98 8,35 ns
alpha-TNF (pg/mL) 29 3,60 17,30 10,53 3,86 31 4,00 238,80 18,36 41,16 ns
Anti-inflammatory
IL-4 (pg/mL) 29 3,40 72,80 10,22 12,42 31 2,10 43,40 12,85 9,92 ns
IL-10 (pg/mL) 29 2,00 50,40 6,18 8,69 31 1,50 16,20 5,66 3,63 ns
gamma-IFN (pg/mL) 29 1,00 5,20 1,94 1,01 31 0,90 26,80 3,40 4,92 ns
erythropoietic modulatories
Erythropoietin (pg/mL) 29 9,90 90,90 37,84 21,75 31 0,30 66,20 24,69 15,54 0,009
GDF-15 (pg/mL) 29 220,00 21283,00 4496,17 4968,49 31 126,00 11349,00 2940,06 3196,42 ns
Hepcidins
serum 25-Hepcidin  (nM/L) 28 0,55 46,39 13,38 10,82 31 0,55 30,49 11,41 8,93 ns
ANAEMIC on T 1 NOT ANAEMIC on T 1
 
 
Table 10 ± Comparison between anaemic and not-DQDPHLFSDWLHQWV¶ 
cytokines profiling on T6 
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Comparison inside the subgroups of patients between findings on T1 and on T6 is 
represented in figure 21. 
In the anaemic group there was no significant differences for haemoglobin mean 
levels that remained low also on T6. Also both the erythropoietic modulating agents 
EPO and GDF-15 had no significant differences in the mean levels on T1-T6 
comparison. Despite the not significant modification of IL-6 values, C-RP serum 
levels were very low on T6 compared to the levels on T1 (p<0.001). Hepcidin 
serum levels agreed more with C-RP serum levels than with IL-6, and they 
significantly reduced on T6 (p=0.002). As consequence, serum iron levels 
increased on T6 and were higher than on T1 (p=0.007) as well as transferrin 
saturation (p=0.014). Even though serum ferritin levels greatly reduced on T6, the 
comparison of mean levels was no significant. 
 
In the not-anaemic group, both C-RP and IL-6 consensually decreased on T6 and 
were much lower than on T1 (p<0.001 and p=0.002, respectively) as well as 
hepcidin serum levels (p<0.001). Serum iron levels and transferrin saturation 
significantly increased on T6 (p<0.001 and p<0.001, respectively). No substantial 
changes were observed in ferritin levels. On the contrary, haemoglobin levels 
decreased on T6, as well as haematocrit and red blood cells count (no change in 
RDW, MCH or MCHC). The mean levels were lower on T6 than on T1 (p<0.001), 
and 11 patients became anaemic.  
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Figure 21 ± Comparison between T1 and T6 in anaemic and not-anameic patients 
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4.8 Hepcidin: a biomarker for anaemia prediction 
 
4.8.1 Hepcidin as prediction biomarker for anaemia  
 
This study focused on anaemia occurring in acutely ill patients mainly caused by 
infections. 
We wonder if occurrence of anaemia (not present at admission) could be predicted. 
We also try to ideQWLI\ ZKLFK µJROG VWDQGDUG¶ WHVW FRXOG KDYH EHHQ XVHIXO IRU WKLV
purpose and what should have been the cut-RII OHYHO IRU ³VDIHW\´ GLVFULPLQDWLQJ
occurrence of anaemia in one week of hospitalization. 
A graph of sensitivity against 1 ± specificity of the "rating" method is called a 
receiver operating characteristic (ROC) curve [87]. The performance of a 
diagnostic variable can be quantified by calculating the area under the ROC curve 
(ROC-AUC). The ideal test would have an AUC of 1, whereas a random guess 
would have an AUC of 0.5 [88]. The larger is the sample size the better it would be 
ensured that one can statistically detect differences in the accuracy of the 
candidate diagnostic test. 
In the overall patients population (N=60),the analysis of ROC curves shows that on 
T1, the levels of IL6, C-RP and hepcidin define a significant AUC for predicting the 
decrease of haemoglobin levels on T6 in all patients; respectively: AUCIL6 = 0.749, 
AUCC-RP = 0.708 and AUChepcidin = 0.686, (threshold 0.5).  
Considering patients who were not-anaemic on T1 (N=31), 11 patients developed 
DQDHPLD RQ 7 WKH ³WUXH DQDHPLD RI DFXWH LQIODPPDWLRQ´ 7KHLU EDVHOLQH
characteristics are described on paragraph 4.5. ROC analysis in this  subgroup 
(figure 22) showed that serum hepcidin levels on T1 yielded an area under the 
curve (AUC) of 0.959, higher than IL-6 (AUC=0.791) and C-RP (AUC=0.668). 
 
 
variables area SE min max p
25-Hepcidin  0.959 0.035 0.891 1,027 <0.0001
IL-6 on T1 0.791 0.091 0.612 0.970 0.970
C-RP on T1 0.668 0.107 0.459 0.877 0.877
95% CI
 
 
Figure 22 ± ROC curves and areas under th curves details  
for prediction of occurring anaemia on T6 in not-anaemic patients on T1 
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When a conFHQWUDWLRQ WKUHVKROG RI VHUXP KHSFLGLQ OHYHOV   Q0/ ZDV
considered, hepcidin yielded 100% sensitivity and 90% specificity for predicting the 
occurrence of anaemia on T6 (in those patients not-anaemic at admission). This 
cut-RIIYDOXHJRWD<RXQGHQ¶VLQdex of 0.9 (maximum value can attain is 1, when the 
test is perfect, and the minimum value is 0, when the test has no diagnostic value) [88].  
 
If a concentration of 5 nM/L of serum 25-hepcidin could be considered the upper 
normal levels in healthy controls [84,91] and 7.6 nM/L the cut-off limit for 
discriminating anaemia of chronic disease in AR patients [80], hepcidin 
concentration of 23 nM/L could be the optimal cut-off to identify subjects with acute 
inflammation (C-RP at least 3 mg/dL) who have an elevated probability to became 
anaemic after at least one week of illness if they are not anaemic at the beginning 
of inflammation. 
 
 
 
 
Figure 23 ± Anaemic and not-anaemic patients on T6  
and distribution according to hepcidin levels on T1.  
Hepcidin serum level cut-off of 23 nM/L,  identified by ROC curve analysis  
for predction of anaemia, correctly identified 23 out of 37 patients anaemic on T6 
 
In the overall patients population (N=60), the proposed hepcidin cut-off level of 23 
nM/L on T1 correctly identified 23 of the 37 anaemic patients on T6. It failed only in 
identifying 5 out of 23 not-anaemic patients on T6 (figure 23). Notably, this cut-off 
levels was identified in the group of not-anaemic patients on T1 who developed 
anaemia on T6, hence we think that it should be advised only in patients without 
anaemia at admission. Further evaluation in wider population with acute 
inflammation/infections is needed in order to validate this proposed discriminatory 
value for developing anaemia after one-week course, despite promptly antibiotic 
and anti-inflammatory therapies.  
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4.9 Acutely ill patients and monocytes expression of hepcidin 
 
Analysis on whole patients population has been performed firstly, then analysis on 
comparison between anaemic and not-anaemic patients on T8 was conducted and 
briefly resumed. Results on peripheral blood isolated monocytes from a sample of 
eight patients with acute infections are showed. 
 
3DWLHQWV¶EDVHOLQHGHPRJUDSKLFVDQGLQIODPPDWRU\FDXVHV 
Among 29 eligible patients enrolled for investigation on T1 and T8, twelve patients 
were excluded because did not complete the study for several causes (5 did not 
meet admission criteria after T1 evaluation; 1 was transfused on day 5; 4 were 
discharged before T8; 1 refused to participate to the study after T1; 1 was 
diagnosed for aggressive non-Hodgkin lymphoma after T1).  
Seventeen subjects satisfied all the inclusion criteria: 7 females and 10 males, 
mean age was 63.1 years-old (SD ±22.3). The comorbidities more frequently 
observed were: cardiovascular diseases such as hypertension (52.9%) and past 
acute myocardial infarction (29.4%), cerebrovascular diseases (23.5%), lung 
GLVHDVHV  DQG GHPHQWLD  7DEOH  GHWDLOV SDWLHQWV¶ EDVHOLQH DQG
characteristics at hospital admission.  
 
BASELINE Mean SD
age at admission 63,12 22,34
lenght-of-hospital stay 10,24 7,69
referred days of inflammation before 
admission
3,41 2,48
N %
male 10 58,8
WHPSHUDWXUH&EHIRUHDGPLVVLRQ 12 70,6
immunocompetent 17 100,0
COMORBIDITIES
Std. 
Deviation
cardiovascular diseases 8 47,1
only hypertension 9 52,9
past acute myocardial infarction 5 29,4
past congestive heart failure 1 5,9
lung diseases 2 11,8
chronic liver diseases 1 5,9
chronic kidney diseases 1 5,9
diabetes 1 5,9
cerebrovascular diseases 4 23,5
dementia 2 11,8
 
Table 11 ± 3DWLHQWV¶EDVHOLQHRQDGPLVVLRQ 
 
All patients received antibiotic treatment within 24h from admission and before 
blood sample obtained. All the causes of inflammation were acute infection (table 
12) involving (some cases overlap), lungs infections accounted for the highest site 
of identified infection (58.8%).  
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ACUTE INFLAMMATORY CAUSES N %
ACUTE INFECTIONS 17 100,0
SITE OF INFECTIONS* N %
blood culture positive infection 1 5,9
lungs 10 58,8
upper airways 3 17,6
gut 3 17,6
urinary tract 2 11,8
* tw o or more overlapping
 
Table 12 ± 3DWLHQWV¶FDXVHRIDFXWHLQIODPPDWLRQ 
 
More than two criteria of Systemic Inflammatory Response Syndrome (SIRS) were 
recognised in 23.5% of subjects (table 13), all of them had pneumonia, hence they 
were considered as having sepsis.  
 
SIRS criteria N %
)HYHU& 5 29,4
+HDUWUDWHEHDWVPLQ 1 5,9
5HVSLUDWRU\EUHDWKVPLQ 7 41,2
White blood cell count >12,000/µL or < 4,000/µL 6 35,3
 
Table 12 ± 3DWLHQWV¶6,56FULWHULD 
 
4.9.2 Whole blood tests, iron and inflammatory parameters 
On first day of hospitalisation (T1), haemoglobin (Hb) mean level was 12.9 g/dL 
(SD ±1.4). On T8, it was 12.45 g/dL (SD ±1.44; p=0.223). No change in red blood 
cells count, haematocrit or RDW (table 13). Considering inflammatory indices, C-
Reactive protein (C-RP) mean serum levels on T1 were higher (13.51 mg/dl; SD 
±9.13) than on T8 (2.65 mg/dl; SD ±3.91; p<0.0001).  
On T1, serum iron levels were low and remained low on T8. Elevated serum ferritin 
levels on T1, were lower but still upper the normal maximal values on T8. 
Transferrin serum levels decreased on T8 relative to T1 (p=0.006), no significant 
change were observed in transferrin saturation, even though its range was wider 
(because of higher levels) than on T1 (see table 13 below).  
 
VARIABLES on T 1 VARIABLES on T8
COMPLETE BLOOD CELLS COUNT Minimum Maximum Mean SD Minimum Maximum Mean SD p
UHGEORRGFHOOVȝ/ 3,52 6,65 4,52 0,71 3,6 4,84 4,23 0,38 ns
mean cells volume (fL) 81 97 87,82 4,71 82 97 87,86 4,87 ns
haemoglobin (g/dL) 10,9 15,2 12,90 1,41 10,1 14,8 12,45 1,44 ns
haematocrit (%) 31 45 38,53 4,08 31 43 37,29 3,83 ns
mean cells haemoglobin 19 33 28,88 3,10 26 34 29,43 2,17 ns
mean cells haemoglobin concentration 32 35 33,53 1,12 32 36 33,57 1,34 ns
red cells distribution widith (RDW) 12 42 15,29 6,94 12 15 13,29 0,83 ns
ZKLWHEORRGFHOOVȝ/ 2,4 17,19 9,22 4,44 2,82 17,52 8,60 3,76 ns
neutrophils 0,34 0,96 0,70 0,15 0,44 0,83 0,65 0,12
eosinophils 0 0,07 0,02 0,02 0 0,34 0,05 0,09
basophils 0 0,01 0,00 0,00 0 0,02 0,01 0,01
lymphocytes 0,03 0,39 0,17 0,10 0,08 0,37 0,23 0,09
monocytes 0,01 0,24 0,11 0,05 0,05 0,11 0,08 0,02
platelets (10*3/ȝ/ 100 305 194,18 61,06 216 484 322,07 89,90 <0.0001
UHWLFXORF\WHVÅ 0,18 1,81 0,91 0,41 0,08 3,5 1,18 0,86 ns
SERUM IRON PARAMETERS
VHUXPLURQȝJG/ 10 59 28,53 15,57 0 109 29,41 38,02 ns
transferrin (mg/dL) 129 228 189,47 28,60 0 234 98,94 99,43 0,006
transferrin saturation (%) 4,12 21,55 11,83 5,70 8,5 42,33 12,16 14,82 ns
ferritin (ng/dL) 127 2322 474,65 509,52 125 780 395,56 207,70 ns
INFLAMMATORY INDICES
erythrocytes sedimentation rate (mm/h) 12 103 59,18 26,94 18 110 47,20 37,07 ns
C-reactive protein (mg/dL) 2,9 31,6 13,51 9,13 0,1 15,6 2,65 3,91 <0.0001
alpha1-acid glicoprotein (mg/dL) 165 248 138,85 89,88 76 250 135,87 76,52 ns
alpha1-antitripsin (mg/dL) 165 341 220,62 49,57 132 389 175,33 93,74 ns
aptoglobin (mg/dL) 176 522 292,06 145,24 136 641 282,60 178,26 ns
 
Table 13 ± 3DWLHQWV¶EORRGWHVWVRQ7DQG7 
ANEMIA of INFLAMMATION  
M.Carrabba 45 
 
4.9.3 Anaemic and not-anaemic patients on T1 
 
As previously showed in paragraph 4.7.1, the17 patients were subdivided in two 
subgroups according to haemoglobin levels on T1.  
Figure 24 shows key results. Except than for haemoglobin (and haematocrit) 
levels, comparison of the means on T1 and T8 between the two subgroups showed 
no significant differences.  
On T1, seven patients were anaemic (mean Hb level 11.63 g/dL, SD ±0.78) and 10 
not-anaemic (mean Hb level 13.79 g/dL, SD ±0.98; p<0.001). On T8, there were no 
differences between the two subgroups in mean Hb levels (anaemic 11.68 g/dL, 
SD ±1.72, not-anaemic 13.03 g/dL, SD ±0.93, respectively).  
Considering the outcome of the 10 patients not-anaemic on T1, 2 became anaemic 
on T8, while among the 7 anaemic patients on T1, 5 remained anaemic on T8.  
C-RP mean levels on T1 (anaemic 12.90 mg/dL, SD ±9.21, not-anaemic 13.93 
mg/dL, SD ±9.54) dropt down to very low levels on T8 (anaemic 2.20 mg/dL, SD 
±1.86, not-anaemic 3.04 mg/dL, SD ±5.22) in all patients of both groups (9 had 
normal levels), except than in one anaemic patient (on T1 2,9 mg/dl, on T8 3,6 
mg/dL). Consensually ESR mean levels were lower on T8 that on T1, but they took 
longer to return to basal levels, as expected. Patients anaemic on T1 were found to 
have higher levels than patients not-anaemic. This finding is consistent with the 
hypothesis that patients with longstanding inflammation, without therapy, 
developed more frequently anaemia.  
Considering iron parameters on T1 and on T8, no significant differences were 
observed between mean levels of serum iron on T1 (anaemic 24.00 µg/dL, SD 
±13.70, not-anaemic 31.70 µg/dL, SD ±16.70) and on T8 (anaemic 21.57 µg/dL, 
SD ±39.81, not-anaemic 34.90 µg/dL, SD ±37.85), transferrin saturation on T1 
(anaemic 9.87%, SD ±5.24, not-anaemic 13.19%, SD ±5.87) and on T8 (anaemic 
9.35%, SD ±15.56, not-anaemic 14.13%, SD ±14.79), and serum ferritin levels on 
T1 (anaemic 578.29 ng/dL, SD ±780.48, not-anaemic 402.10 ng/dL, SD ±203.04) 
and on T8 (anaemic 496.67 ng/dL, SD ±250.82, not-anaemic 345.00 ng/dL, SD 
±186.15). Also comparisons of T1 versus T8 finding into the same subgroup were 
not significant different.  
In conclusion, in this patients population of 17 subjects, comparison of findings on 
T1 and T8 between anaemic and not-anaemic was congruent and showed 
comparable results of the analysis performed on the wider sample size population 
showed on paragraph 4.7.1.  
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Figure 24 ± comparison between anaemic and not-anaemic patients on T1. 
The two subgroups key results of Hb, C-RP, ERS, serum iron, transferrin saturation 
and ferritin levels are shown in box-plot with mean and percentages (25% - 75%). 
 
 
 
 
 
 
ANEMIA of INFLAMMATION  
M.Carrabba 47 
 
4.9.4 Acutely ill patients and circulating monocytes expression of 
hepcidin 
 
4.9.4.1 Monocytes-derived mRNA levels of hepcidin on T1 and on T8 
A representative sample size consistent of 8 patients was considered. Mean age 
was 66.5 years (SD ±20.17; range 28 - 88yrs). Underlying causes of acute infection 
and hospitalization were: pneumonia (N=3), upper airways infection (N=2), gut 
infection (N=2), prostatitis as urinary tract infection (N=1). The mRNA levels of  
hepcidin (HAMP mRNA) DQG RI ȕ-DFWLQ LQ SDWLHQWV¶ SHULSKHUDO EORRG QHJDWLYH
isolated monocytes were determined on both T1 and T8. Circulating monocytes 
were negative isolated (see methods on paragraph 3.3.5) in order to not activate 
WKHFHOOV IXUWKHU7KHȕ-actin mRNA levels in monocytes have been described as 
good housekeeping control for HAMP mRNA analysis [47], and were therefore 
used to standardize hepcidin mRNA levels to compensate for potential variations of 
total RNA used in individual assays. The mean of relative mRNA levels of hepcidin 
(x105) on T1 was 7.37 (95% CI: 0.81-13.93), higher than that found on T8: 5.32 
(95% CI: 0.42-10.21), see figure 25. 
 
 
 
Figure 25 ± Hepcidin mRNA levels on T1 and T8 (relative to ȕ-actin mRNA x105). 
 
Correlation between serum C-53 OHYHOV DQG OHYHOV RI SDWLHQWV¶ FLUFXODWLQJ
monocytes-derived HAMP mRNA were performed.  
No significant correlation was found on T1 nor on T8 (figure 26). Otherwise, a 
positive trend was found between C-RP serum levels on T1 and monocytes-
derived HAMP mRNA on T8 (figure 26). It could be hypothesised that the impact of 
inflammation on significant induction of HAMP transcription by peripheral blood 
monocytes takes longer to be observed in vivo than in the in vitro endotoxemia 
models [47,49,98,99,100]. The lack in the measurement of hepcidin produced by 
circulating monocytes is one of the main limit of this study, together to the low 
sample size. 
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Figure 26 ± Correlation between hepcidin mRNA levels on T1 and T8 (relative to く-
actin mRNA x105) and C-RP serum levels on T1 andT8, respectively. On the left, 
correlation between hepcidin mRNA levels on T8 and serum C-RP levels on T1. 
 
4.9.4.2 Monocytes-derived mRNA levels of hepcidin and ferritin serum levels 
We found no correlation between serum iron levels and circulating monocytes-
derived HAMP mRNA, nor on T1 neither on T8. 
Monocytes-derived HAMP mRNA had a negative correlation between HAMP 
mRNA levels on T8 and serum ferritin levels on T8 (r=-0.946, p=0.054) as shown in 
figure 27, while no correlation was found on T1 (figure 27, right).  
The role of circulating monocytes-derived hepcidin is still not clarified [101,102]. 
Our finding could suggest that autocrine hepcidin production by monocytes 
increases iron retention, but we could not explain why it happens only after 8-days 
course of documented acute inflammation.  
 
 
Figure 27 ± Correlation between hepcidin mRNA levels  
on T1 and T8 (relative to く- actin mRNA x105) and serum ferritin levels (log) 
 on t1 and on T8, respectively. Significant correlation on T8 between HAMP mRNA  
and serum ferritin log levels is shown  (r=-0.953, p=0.047). 
 
The lack of correlation observed on T1 is similar to the finding by Wu et al. [49], but 
unfortunately, Authors tested their patients only once, at the sepsis onset. Findings 
by Theurl et al. [47] could not be considered for comparison, mainly because they 
investigated anaemic patients without any timing of the inflammation onset. 
Moreover, their patients population was affected by inhomogeneous causes of 
inflammation. 
On the other hand, both these Authors argued on the lack of correlation between 
monocyte-derived HAMP mRNA and serum ferritin levels in their studies [101]. 
Indeed, nor Theurl  et al. [47] neither Wu et al. [49] found any correlation between 
circulating ferritin levels were with HAMP mRNA levels determined in monocytes of 
patients with anaemia of chronic disease [47] and severe sepsis [49]. They tried to 
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impute the lack in correlation to the fact that serum ferritin levels under 
inflammatory conditions are related to iron overload, regulatory effects of cytokines 
on ferritin expression, and cellular apoptosis. Unlike hepcidin expression in the 
liver, HAMP cannot be induced in monocytes or macrophages upon iron challenge 
[33,47], and in their opinion, this partly explains the lack of correlation.  
Wu et al. [49], commented that the lack of correlation between monocytes HAMP 
mRNA and serum ferritin would be ascribed to a different role of hepcidin produced 
by leukocytes in sepsis from that produced by hepatic cells. 
 
4.9.4.3 Circulating monocytes IL-6 receptor, monocytes-derived mRNA levels  
of hepcidin and ferritin serum levels 
In 20 of the 60 patients with acute inflammation investigated on T1 and T6 (see 
paragraphs 4.1 and the following), the expression of IL-6 receptor (IL-6R) on the 
membranes of circulating monocytes was evaluated by flowcytometric analysis.  
The functional IL-6R complex consists of IL-6R (CD126) and gp130. CD 126 is 
constitutionally expressed on cells membranes and by itself does not induce signal 
transduction. IL-6/CD126 complex induces the formation of a gp130/gp130 
homodimer, which results in transmembrane signalling [103].  
On T1, the mean expression of CD126 was 42.31 MFI (SE ±1.28), on T6 it was 
40.80 MFI (SE ±1.79), no differences were observed. On T1, gp130 mean 
expression was 10.78 MFI (SE ±0.65), on T6 it was 11.36 MFI (SE ±0.45), no 
differences were observed (see figure 28, left). Our data are similar to those of 
Marsik et al. [103], who investigated the enhanced expression of gp130 in 
endotoxemia induced by LPS 
A positive correlation between gp130 expression on T6 and serum ferritin log levels 
on T6 was found (r=0.523, p=0.018; figure 28, right). No significant correlations 
were found on T1 levels. This finding could suggest that when inflammatory 
network is well established (on T8) and circulating monocytes are highly activated, 
the lower is the expression of gp130 (signalling transduction activated), the higher 
is the monocytes iron-retention by induction of HAMP transcription, as expected.  
 
 
Figure 28 ± CD126 and gp130 expression on T1 and T6, on the left. Correlation 
between gp130 on T6 and serum ferritin levels on T6 (log), on the right. 
 
In the 8 patients, whose HAMP mRNA derived by the circulating monocytes was 
analysed, IL-6 receptor expression on T1 and on T8 resembled the one observed 
in the 20 patients described above. No differences were observed on T1 and on T8 
between the circulating monocytes membranes expression of both gp130 (12.13 
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MFI, SE ±1.32; 13.23 MFI, SE ±0.44; respectively) and CD 126 (34.27 MFI, SE 
±5.80; 48.22 MFI, SE ±2.08; respectively), as shown in figure 29 (left). The 
negative correlation between gp130 expression on T8 and serum ferritin levels on 
T8 were confirmed (r=-1.00, p=0.01). On T8, a negative correlation also between 
HAMP mRNA and gp130 expression was found, as shown in figure 29 (right).  
These findings on T8 show that the lower is gp130, the highest is monocytes 
derived HAMP mRNA and, consequently, the lower is serum ferritin levels (figure 
27, right). It could be hypothesised that induction of HAMP mRNA expression in 
circulating monocytes partially depends on gp130 signalling pathways. More data 
are needed, especially serum cytokines levels profiling of IL-6 and TNF-alpha.  
 
  
 
Figure 29 ± CD126 and gp130 expression on T1 and T8, on the left. Correlation 
between gp130 on T8 and circulating monocyte HAMP mRNA levels on T8  
UHODWHGWRȕ-actin, x105), on the right. 
 
4.9.4.4 Circulating monocytes-derived mRNA levels: T1 and T8 modification 
Paired comparison between peripheral monocytes HAMP mRNA levels on T1 and 
on T8 were performed in 6 patients. All the patients lost haemoglobin on T8 (figure 
30, left). Five patients had also a decrease in C-RP levels more than 70% (figure 
30, right). The two patients with gut infection were excluded, as well the youngest 
and the oldest patient (28 years-old and 88 years-old, respectively).  
 
 
Figure 30 ± Percentage of haemoglobin loss on T8 relative to T1 (left). 
Percentage of decrease in C-RP levels on T8 relative to T1 (right). 
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The relative mRNA levels of hepcidin (x105) derived by circulating monocytes on 
T1 were 9.26 (95% CI: 0.55-17.97), higher than those found on T8 5.89 (95% CI: -
1.22-13.00), see figure 31 (left). 
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Figure 30 ± Hepcidin mRNA mean levels on T1 and T8 (relative to く-actin mRNA 
x105), on the left. Paired hepcidin mRNA levels on T1 and T8, on the right. 
 
All the patients, except one, showed a decrease in HAMP mRNA levels on T8 
related to T1 (figure 30, right). The fold change in HAMP mRNA T8 expression 
compared to T1 is detailed in figure 31 (left).  
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Figure 31 ± Hepcidin mRNA fold change in T8 relative to T1 levels (normalised to 
く-actin mRNA x105), on the left. Hepcidin mRNA fold decrease expression on T8 
relative toT1 levels (normalised to く-actin mRNA x105), on the right. 
     
In figure 31 (right) is showed the reduction in circulating monocytes HAMP mRNA 
levels after 8-days course of acute inflammation and therapies. As expected, 
antibiotics and anti-inflammatory levels reduced also HAMP expression in those 
patients who had a decrease in C-RP serum levels. 
However, no correlations were found between this fold of reduced expression with 
the degree of loss in haemoglobin levels nor with the decrease of C-RP serum 
levels. Neither the change in ferritin serum levels nor in iron serum levels showed 
correlation.  
To our knowledge, this is the first study that investigated circulating monocytes-
derived HAMP mRNA on admission and few days after (8 days). Other patients are 
under evaluation in order to better explore this issue in a wider population. 
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5. CONCLUSIONS 
 
In this prospective investigation on patients hospitalised for acute inflammation the 
close link between immunity and iron is evaluated and demonstrated.  
Hepcidin-25 is increased during acute inflammation. The inflammatory cytokines 
pattern observed in vivo in this study resembles the one described in experimental 
models of endotoxemia showed by Kemna et al. [32] and by Theurl et al.[47]. 
Hepcidin serum levels, haemoglobin and iron parameters are very similar to the 
ones found by van Eijk et al. in their investigation in septic patients admitted to ICU 
[81]. We found that in 60 acutely ill patients (95% affected by infections), the 
degree of inflammation, indicated by IL-6 and C-RP levels, is associated with 
elevated concentrations of hepcidin, low iron serum levels, high transferrin 
saturation and very high ferritin serum levels. Moreover, persistently increased 
levels of hepcidin-25 on T1 and on T6 are associated with a decrease in 
haemoglobin during hospitalization. Patients (N=26) anaemic on T1 were still 
anaemic after one week. Erythropoiesis was still blunted in these patients, despite 
higher erythropoietin serum levels than not-anaemic patients. The high levels of 
GDF-15 and hepcidin could have a role in the ineffective erythropoiesis.  
We observed acute ill patients (N=31) admitted with normal haemoglobin levels 
develop anaemia after the first week of hospitalization. Analysing this subset of 
patients¶KHSFLGLQ OHYHOV, we found that a cut-off level of hepcidin concentration of 
23 nM/L was able to predict anaemia occurrence after one week with 100% of 
sensitivity and 90% of specificity.  
As was previously described [47,49], we also demonstrated expression of hepcidin 
mRNA in the circulating monocytes of the acutely ill patients. We found that its 
expression seems to be delayed in vivo by the persistence of inflammation during 
the first week of hospitalization. Indeed, we found that the higher was the 
inflammation on T1, the higher was hepcidin mRNA expression in circulating 
monocytes on T8. Moreover we found negative correlation between mRNA levels 
of monocytes-derived hepcidin and serum ferritin, especially on T8. Analysis of IL-6 
functional receptor (CD126 and gp130) on circulating monocytes showed a 
negative correlation with monocytes-derived hepcidin mRNA, and positive 
correlation with serum ferritin levels. These findings could suggest that gp130 
expressed on monocytes membrane might have a role in the signalling for hepcidin 
mRNA transcription and, consequently, iron retention. 
 
The new light in the corner of the mechanisms behind anaemia of acute 
inflammation, led to reconsider old therapies and explore new approaches. 
Transfusion is the oldest (and expensive) way of increasing haemoglobin, but its 
adverse effects are many, and it is not clear that the desired benefits of increased 
oxygen delivery and consumption at the cellular level actually occur. 
Erythropoietin therapy is effective (and expensive), but it takes time to augment 
erythropoiesis and is limited by contraindications and side effects. And perhaps, 
there are likely to be unintended consequences we have not yet discovered. 
Moreover, to date, there is no recommendation for the use of erythropoietin in 
critically ill patients, even though anaemic.  
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However, in anaemia of chronic kidney disease, it is well recognized that response 
to erythropoietin is greatly enhanced by intravenous iron. But iron may also be 
proposed to correct iron deficiency, even in the presence of inflammation, as it is 
now proposed to treat anaemia caused by cancer [1].  
Iron may be given either by enteral or intravenous way. Recently, a hepcidin/ferritin 
driven approach has been proposed [104]. If iron is administrated by the enteral 
routes, its absorption may be reduced (secondary to the hepcidin-linked decrease 
in ferroportin in duodenal cells). On the other hand, in anaemia of inflammation 
there is a functional iron-deficiency, hence, the use of large amounts of iron, 
exceeding the transferrin iron-binding capacity, may promote free iron, which is 
known to induce oxidant stress [38]. Moreover, the link between iron and infection 
seems to suggest that there is an association between hyperferritinemia and the 
likelihood of infection [9], which could be harmful in the setting of anaemia by acute 
infection. 
Novel therapeutics, such as suppressing the inflammatory response, all deserve 
careful study for their potential benefits and careful observation for unintended side 
effects. Indeed, to block the inflammatory response via antibodies to cytokines, 
other acute phase reactants, or their receptors, is one of the new strategy for 
anaemia of inflammation. It has been demonstrated that IL-6 antibodies block the 
effect of LPS on hepatocytes in vitro and in mouse-model [72]. Anti-hepcidin 
antibodies could also block the suppressive effect on iron regulation [67]. 
Therefore, as hepcidin has antimicrobial properties, it may play a not yet 
discovered role in the fight against infection. Hence, further investigation are 
mandatory to prove these targets effectiveness and safety on human subjects. 
 
In conclusion, this analysis on acutely ill patients, its exhaustive characterization of 
the erythropoietic, inflammatory and iron-profile confirmed in vivo what many 
recently studies proved in vitro. We shows that the inflammation that occurs in 
acute illness can contribute to the development of anaemia by fine tuning of 
mechanisms that involves either cytokines, hepcidin, iron and erythropoiesis.  
Hepcidin derived by circulating monocytes has a not yet clarified role either for 
autocrine and for endocrine effects. Moreover, signalling-inducing hepcidin 
expression in human peripheral monocytes (and leukocytes) has been not yet 
completely understood. 
The comprehension of (liver-derived) hepcidin regulatory mechanisms have 
changed approach to the differential diagnosis [70,80] and treatment of anaemia 
[3]. However, before hepcidin measurements can be used in routine clinical 
practice, efforts will be required to harmonize the different assays, to define clinical 
decision limits, and to increase assay availability for clinical laboratories. 
The major benefit of understanding iron regulation in acute inflammation will be a 
relevant effect on decreasing healthcare requirements and substantially in-hospital 
stay, diagnostic investigations and, finally, healthcare costs. 
The knowledge of these mechanisms should guide the clinical management of the 
anaemia of acute inflammation, whose treatment is still really challenging.  
 
 
 
ANEMIA of INFLAMMATION  
M.Carrabba 54 
 
REFERENCES 
 
1. :HLVV * *RRGQRXJK /7 ³$QHPLD RI FKURQLF GLVHDVH´ New England 
Journal of Medicine, Vol 352, 2005; pp. 1011-1023. 
2. Lasocki S., Longrois D., 0RQWUDYHUV3%HDXPRQW&³+HSFLGLQDQGDQHPLD
RIWKHFULWLFDOO\LOOSDWLHQW´$QHVWKHVLRORJ\9ROSS-94. 
3. +D\GHQ 6- $OEHUW 7- :DWNLQV 75 6ZHQVRQ (5 ³$QHPLD LQ FULWLFDO
illness: insights into etiology, consequences, and managemHQW´$P-5HVSLU&ULW
Care Med, Vol 185, no. 10, 2012, pp. 1049-1057.  
4. :DOVK76/HH5-0DFLYHU&5HWDO ³$QHPLDGXULQJDQGDWGLVFKDUJH
IURP LQWHQVLYHFDUH WKH LPSDFWRI UHVWULFWLYHEORRG WUDQVIXVLRQSUDFWLFH´ ,QWHQVLYH
Care Med, Vol 32, 2006, pp.100-109.  
5. %DWHPDQ $3 0F$UGOH ) :DOVK 76 ³7LPH FRXUVH RI DQHPLD GXULQJ VL[
months follow up following intensive care discharge and factors associated with 
LPSDLUHGUHFRYHU\RIHU\WKURSRLHVLV´&ULW&DUH0HG9ROSS-1912. 
6. EisenstDHGW 56 ³7KH SUHYDOHQFH RI DQHPLD LQ SULPDU\ FDUH´ 3RVWJUDG
Medicine, Vol 116, no. S5, 2004, pp. 7-11. 
7. *RRGQRXJK /7 1HPHWK ( *DQ] 7 ³'HWHFWLRQ HYDOXDWLRQ DQG
management of iron-UHVWULFWHGHU\WKURSRLHVLV´%ORRG9ROQR-
4761. 
8. -XUDGR5/ ³,URQ LQIHFWLRQVDQGDQHPLDRI LQIODPPDWLRQ´&OLQLFDO ,QIHFWLRXV
Disease, Vol 25, 1997, pp. 888-895. 
9. *DQ] 7 ³,URQ LQ LQQDWH LPPXQLW\ VWDUYH WKH LQYDGHUV´ &XUUHQW 2SLQLRQ LQ
Immunology, Vol 21, 2009, pp. 63-67. 
10. *DQ] 7 ³+HSFLGLQ ² a regulator of intestinal iron absorption and iron 
UHF\FOLQJ E\ PDFURSKDJHV´ %HVW 3UDFWLFH 	 5HVHDUFK &OLQLFDO +DHPDWRORJ\ 9RO
18, no. 2, 2005, pp. 171-182. 
11. 3LJHRQ& ,O\LQ*&RXUVHODXG%HWDO ³$QHZPRXVH OLYHUVSHFLILFJHQH
encoding a protein homologous to human antimicrobial peptide hepcidin, is 
RYHUH[SUHVVHGGXULQJLURQRYHUORDG´-%LRO&KHP9ROSS-7819. 
12. -RUGDQ -% 3RSSH / +DQLX 0 HW DO ³+HSFLGLQ UHYLVLWHG GLVXOILGH
FRQQHFWLYLW\ G\QDPLFV DQG VWUXFWXUH´ - %LRO &KHP 9ol 284, 2009, pp. 24155-
24167. 
13. )DUQDXG63DWHO$(YDQV5:³0RGHOOLQJRIDPHWDO-FRQWDLQLQJKHSFLGLQ´
Biometals, Vol 19, 2006, pp. 527-533.  
14. 3DUN &+ 9DORUH (9 :DULQJ $- *DQ] 7 ³+HSFLGLQ D XULQDU\
antimicrobial peptide synthesized in the OLYHU´J Biol Chem, Vol 276, no. 11, 2001, 
pp. 7806-7810. 
15. .UDXVH $ 1HLW] 6 0DJHUW +- HW DO ³/($3-1, a novel highly disulfide-
ERQGHGKXPDQSHSWLGHH[KLELWVDQWLPLFURELDODFWLYLW\´FEBS Letter, Vol 480, 2000, 
pp. 147-150. 
ANEMIA of INFLAMMATION  
M.Carrabba 55 
 
16. 9DORUH (9 *DQ] 7 ³3osttranslational processing of hepcidin in human 
KHSDWRF\WHVLVPHGLDWHGE\WKHSURKRUPRQHFRQYHUWDVHIXULQ´Blood Cells Mol Dis, 
Vol 40, 2008, pp.132-138. 
17. .HPQD (+ 7MDOVPD + 3RGXVW 91 6ZLQNHOV ': ³0DVV VSHFWURPHWU\-
based hepcidin measurements in serum and urine: analytical aspects and clinical 
LPSOLFDWLRQV´Clin Chem, Vol 53, 2007, pp. 620-628. 
18. Rivera S., Nemeth E., Gabayan V., Lopez M.A., Farshidi D., Ganz T., 
³6\QWKHWLF KHSFLGLQ FDXVHV UDSLG GRVH-dependent hypoferremia and is 
concentrated in ferroportin-FRQWDLQLQJ RUJDQV´ Blood, Vol 106, 2005, pp. 2196-
2199. 
19. 1HPHWK(3UH]D*&-XQJ&/.DSODQ-:DULQJ$-*DQ]7³7KH1-
terminus of hepcidin is essential for its interaction with ferroportin: structure-
IXQFWLRQVWXG\´Blood, Vol 107, 2006, pp. 328-333. 
20. 3HVORYD * 3HWUDN - .X]HORYD . HW DO ³Hepcidin, the hormone of iron 
metabolism, is bound specifically to alpha-2-PDFURJOREXOLQ LQ EORRG´ Blood, Vol 
113, 2009, pp. 6225-6236.  
21. 1LFRODV*%HQQRXQ03RUWHX$HWDO ³Severe iron deficiency anemia in 
WUDQVJHQLFPLFHH[SUHVVLQJ OLYHUKHSFLGLQ´ Proceedings of the National Academy 
of Sciences, Vol 99, 2002, pp. 4596-4601.  
22. Nicolas G., Bennoun M., Devaux I., Beaumont C., Grandchamp B., Kahn A., 
Vaulont S., ³/DFNRIKHSFLGLQJHQHH[SUHVVLRQDQGVHYHUH WLVVXH LURQRYHUORDG LQ
XSVWUHDPVWLPXODWRU\IDFWRU86)NQRFNRXWPLFH´Proceedings of the National 
Academy of Sciences, Vol 98, 2001, pp. 8780-8785.  
23. 1HPHWK ( *DQ] 7 ³7KH UROH RI KHSFLGLQ LQ LURQ PHWDEROLVP´ Acta 
Haematologica, Vol 122, no. 2-3, 2009, pp. 78-86. 
24. *DQ]7³+HSFLGLQDQGLURQUHJXODWLRQ\HDUVODWHU´Blood, Vol 117, no. 17, 
2011, pp. 4425-4433. 
25. 5RHWWR $ 3DSDQLNRODRX * 3ROLWRX 0 HW DO ³Mutant antimicrobial peptide 
hepcidin is DVVRFLDWHGZLWKVHYHUHMXYHQLOHKHPRFKURPDWRVLV´Nat Genet, Vol 33, 
2003, pp. 21-22. 
26. 3DSDQLNRODRX * 6DPXHOV 0( /XGZLJ (+ HW DO ³0XWDWLRQV LQ +)(
cause iron overload in chromosome 1q-OLQNHG MXYHQLOH KHPRFKURPDWRVLV´ Nat 
Genet, Vol 36, 2004, pp. 77-82. 
27. %ULGOH.5)UD]HU'0:LONLQV6-HWDO´Disrupted hepcidin regulation in 
HFE-associated haemochromatosis and the liver as a regulator of body iron 
KRPRHRVWDVLV´Lancet, Vol 361, 2003, pp. 669-673. 
28. Nemeth E., Valore E.V., Territo M., et al ³Hepcidin, a putative mediator of 
anemia of inflammation, is a type II acute-SKDVHSURWHLQ´Blood, Vol 101, 2003 pp. 
2461-2463. 
29. :HLQVWHLQ'$5R\&1)OHPLQJ0' HWDO ´Inappropriate expression of 
hepcidin is associated with iron refractory anemia: implications for the anemia of 
FKURQLFGLVHDVH´Blood, Vol 100, no. 10, 2002, pp. 3776-3781. 
ANEMIA of INFLAMMATION  
M.Carrabba 56 
 
30. )LQEHUJ.(+HHQH\00&DPSDJQD'5HWDO ³Mutations in TMPRSS6 
cause iron-UHIUDFWRU\LURQGHILFLHQF\DQHPLD,5,'$´Nat Genet, Vol 40, 2008, pp. 
569-571. 
31. 1HPHWK ( 5LYHUD 6 *DED\DQ 9 HW DO ³IL-6 mediates hypoferremia of 
LQIODPPDWLRQE\LQGXFLQJWKHV\QWKHVLVRIWKHLURQUHJXODWRU\KRUPRQHKHSFLGLQ´J 
Clin Invest, Vol 113, no. 9, 2004, pp. 1271-1276. 
32. Kemna E., Pickkers P., Nemeth E., van der +RHYHQ+6ZLQNHOV' ³7LPH-
course analysis of hepcidin, serum iron, and plasma cytokine levels in humans 
LQMHFWHGZLWK/36´Blood, Vol 106, no. 5, 2005, pp. 1864-1866. 
33. Peyssonnaux C., Zinkernagel A.S., Datta V., Lauth X., Johnson R.S., Nizet V., 
³7/5-dependent hepcidin expression by myeloid cells in response to bacterial 
SDWKRJHQV´Blood, Vol 107, 2006, pp. 3727-3732. 
34. Verga Falzacappa M.V., Vujic S.M., Kessler R., et al., ³67$7 PHGLDWHV
KHSDWLFKHSFLGLQH[SUHVVLRQDQGLWV LQIODPPDWRU\VWLPXODWLRQ´Blood, Vol 109, no. 
1, 2007, pp. 353-358. 
35. 3LHWUDQJHOR$'LHUVVHQ89DOOL/HWDO³67$7LVUHTXLUHGIRU,/-6-gp130-
GHSHQGHQWDFWLYDWLRQRIKHSFLGLQ LQYLYR´Gastroenterology, Vol 132, no. 1, 2007, 
pp. 294-300. 
36. :ULJKWLQJ '0 $QGUHZV 1& ³,QWHUOHukin-6 induces hepcidin expression 
WKURXJK67$7´Blood, Vol 108, 2006, pp. 3204-3209. 
37. 0DOLNHQ%'1HOVRQ-(.RZGOH\.9´7KHKHSFLGLQFLUFXLWVDFWEDODQFLQJ
LURQDQGLQIODPPDWLRQ´Hepatology, Vol 53, no. 5, 2011, pp. 1764-1766. 
38. Hentze M.W., MuckHQWKDOHU 08 *DO\ % &DPDVFKHOOD & ³7ZR WR WDQJR
UHJXODWLRQRI0DPPDOLDQLURQPHWDEROLVP´Cell, Vol 142, 2010, pp. 24-38. 
39. %HNUL 6 *XDO 3 $QW\ 5 HW DO ³,QFUHDVHG DGLSRVH WLVVXH H[SUHVVLRQ RI
hepcidin in severe obesity is independent from diabHWHV DQG 1$6+´
Gastroenterology, Vol 131, 2006, pp. 788-796. 
40. 1JX\HQ 1% &DOODJKDQ .' *KLR $- +DLOH '- <DQJ ) ³+HSFLGLQ
H[SUHVVLRQ DQG LURQ WUDQVSRUW LQ DOYHRODU PDFURSKDJHV´ Am J Physiol Lung Cell 
Mol Physiol, Vol 291, no. 3, 2006, pp. L417-425.  
41. 0HUOH8)HLQ(*HKUNH6*6WUHPPHO:.XODNVL]+³7KHLURQUHJXODWRU\
peptide hepcidin is expressed in the heart and regulated by hypoxia and 
LQIODPPDWLRQ´Endocrinology, Vol 148, 2007, pp. 2663-2668. 
42. Kulaksiz H., Fein E., Redecker P., Stremmel W., Adler G., Cetin Y., 
³3DQFUHDWLF EHWD-cells express hepcidin, an iron-XSWDNH UHJXODWRU\ SHSWLGH´ J 
Endocrinol, Vol 197, 2008 pp. 241-249.  
43. .XODNVL] + 7KHLOLJ ) %DFKPDQQ 6 HW DO ³7KH LURQ-regulatory peptide 
hormone hepcidin: expression and cHOOXODUORFDOL]DWLRQLQWKHPDPPDOLDQNLGQH\´J 
Endocrinol, Vol 184, 2005, pp. 361-370.  
44. Gnana-Prakasam J.P., Martin P.M., Mysona B.A., Roon P., Smith S.B., 
*DQDSDWK\ 9 ³+HSFLGLQ H[SUHVVLRQ LQ PRXVH UHWLQD DQG LWV UHJXODWLRQ YLD
lipopolysaccharide/Toll-like receptor- SDWKZD\ LQGHSHQGHQW RI +IH´ Biochem J, 
Vol 411, 2008, pp. 79-88. 
ANEMIA of INFLAMMATION  
M.Carrabba 57 
 
45. ,VRGD 0 +DQDZD + :DWDQDEH 5 HW DO ³([SUHVVLRQ RI WKH SHSWLGH
hormone hepcidin increases in cardiomyocytes under myocarditis and myocardial 
LQIDUFWLRQ´J Nutr Biochem, Vol 21, 2010, pp. 749-756. 
46. 7KHXUO,0DWWOH96HLIHUW00DULDQL00DUWK&:HLVV*³'\VUHJXODWHG
monocyte iron homeostasis and erythropoietin formation in patients with anemia of 
FKURQLFGLVHDVH´Blood, Vol 107, 2006, pp. 4142-4148.  
47. Theurl I.7KHXUO06HLIHUW0HWDO³$XWRFULQHIRUPDWLRQRIKHSFLGLQLQGXFHV
LURQUHWHQWLRQLQKXPDQPRQRF\WHV´Blood, Vol 111, 2008, pp. 2392-2399. 
48. Pinto J.P., Dias V., Zoller H., Porto G., Carmo H., Carvalho F. and de Sousa 
0 ³+HSFLGLQ PHVVHQJHU 51$ H[SUHVVLRQ LQ KXPDQ O\PSKRF\WHV´ Immunology, 
Vol 130, no. 2, 2010, pp. 217-230.  
49. :X 6- =KDQJ . /Y & HW DO ³1XFOHDU IDFWRU-kB mediated 
lipopolysaccharide-induced mRNA expression of hepcidin in human peripheral 
EORRGOHXNRF\WHV´Innate Immunity, Vol 18, no. 2, 2012, pp. 318-324. 
50. Coyne D.W., Hepcidin: clinical utility as a diagnostic tool and therapeutic 
target´Kidney International, Vol 80, no. 3, 2011, pp. 240-244.  
51. Ashby D5*DOH'3%XVEULGJH0HWDO ³(U\WKURSRLHWLQDGPLQLVWUDWLRQ LQ
KXPDQV FDXVHV D PDUNHG DQG SURORQJHG UHGXFWLRQ LQ FLUFXODWLQJ KHSFLGLQ´
Haematologica, Vol 95, no. 3, 2010, pp. 505-508 
52. +XDQJ+&RQVWDQWH0/D\RXQ$6DQWRV00³&RQWULEXWLRQRf STAT3 and 
60$' SDWKZD\V WR WKH UHJXODWLRQ RI KHSFLGLQ E\ RSSRVLQJ VWLPXOL´ Blood, Vol 
113, no. 15, 2009, pp. 3593-3599. 
53. )ODQDJDQ-03HQJ+:DQJ/HWDO³6ROXEOHWUDQVIHUULQUHFHSWRU-1 levels 
LQPLFHGRQRWDIIHFWLURQDEVRUSWLRQ´Acta Haematol, Vol 116, 2006, pp. 249-254.  
54. Pinto J.P., Ribeiro S., Pontes H., Thowfeequ S., Tosh D., Carvalho F., Porto 
* ³(U\WKURSRLHWLQ PHGLDWHV KHSFLGLQ H[SUHVVLRQ LQ KHSDWRF\WHV WKURXJK (325
VLJQDOLQJDQGUHJXODWLRQRI&(%3DOSKD´Blood, Vol 111, 2008, pp. 5727-5733 
55. 9RNXUND0.ULMW-6XOF.1HFDV(³+HSFLGLQP51$OHYHOVLQPRXVHOLYHU
UHVSRQGWRLQKLELWLRQRIHU\WKURSRLHVLV´Physiol Res, Vol 55, 2006, pp. 667-674.  
56. 3DN 0 /RSH] 0$ *DED\DQ 9 *DQ] 7 5LYHUD 6 ³6XSSUHVVLRQ RI
hepcidin during anemiDUHTXLUHVHU\WKURSRLHWLFDFWLYLW\´Blood, Vol 108, 2006, pp. 
3730-3735. 
57. 7DQQR 7 3RUD\HWWH 3 6ULSLFKDL 2 HW DO ³,GHQWLILFDWLRQ RI 7:6* DV D
second novel erythroid regulator of hepcidin expression in murine and human 
FHOOV´Blood, Vol 114, 2009, pp. 181-186. 
58. &KRX 67 :HLVV 0- ³'LVHDVHG UHG EORRG FHOOV WRSSOH LURQ EDODQFH´ Nat 
Med, Vol 13, 2007, pp. 1020-1021.  
59. 7DQQR 7 %KDQX 19 2QHDO 3$ HW DO ³+LJK OHYHOV RI *') LQ
thalassemia suppress expression of the iron regulatory protein hepFLGLQ´Nat Med, 
Vol 13, 2007, pp. 1096-1101. 
60. 1LFRODV * &KDXYHW & 9LDWWH / HW DO ´The gene encoding the iron 
UHJXODWRU\SHSWLGHKHSFLGLQ LVUHJXODWHGE\DQHPLDK\SR[LDDQG LQIODPPDWLRQ´ J 
Clin Invest, Vol 110, 2002, pp. 1037-1044.    
ANEMIA of INFLAMMATION  
M.Carrabba 58 
 
61. Peyssonnaux & =LQNHUQDJHO $6 6FKXHSEDFK 5$ HW DO ³5HJXODWLRQ RI
iron homeostasis by the hypoxia-LQGXFLEOH WUDQVFULSWLRQ IDFWRUV +,)V´ J Clin 
Invest, Vol 117, no. 7, 2007, pp. 1926-1932. 
62. 1HPHWK ( ³7DUJHWLQJ WKH KHSFLGLQ-ferroportin axis in the diagnosis and 
WUHDWPHQWRIDQHPLDV´Adv Hematol, Vol 2010, 2010, pp. 750643. 
63. *DQ] 7 ³0ROHFXODU SDWKRJHQHVLV RI DQHPLD RI FKURQLF GLVHDVH´ Pediatric 
Blood and Cancer, Vol 46, no. 5, 2006, pp. 554-557. 
64. Ganz T., Olbina G., Girelli D., Nemeth E., and Westerman M., ³,PPXQRDVVD\
IRUKXPDQVHUXPKHSFLGLQ´Blood, Vol 112, no. 10, 2008, pp. 4292±4297.   
65. 6HPULQ * )LVKPDQ '6 %RXVYDURV $ HW DO ³,PSDLUHG LQWHVWLQDO LURQ
DEVRUSWLRQ LQ &URKQ¶V GLVHDVH FRUUHODWHV ZLWK GLVHDVH DFWLYLW\ DQG PDUNHUV RI
LQIODPPDWLRQ´Inflammatory Bowel Diseases, Vol 12, no. 12, 2006, pp. 1101±1106. 
66. 6KDUPD 6 1HPHWK ( &KHQ <+ HW DO ³,QYROYHPHQW RI KHSFLGLQ LQ WKH
DQHPLDRIPXOWLSOHP\HORPD´Clinical Cancer Research, Vol 14, no. 11, 2008, pp. 
3262±3267.   
67. Sasu B.J., Cooke K.S., ArvHGVRQ7/HWDO³$QWLKHSFLGLQDQWLERG\WUHDWPHQW
modulates iron metabolism and is effective in a mouse model of inflammation 
LQGXFHGDQHPLD´Blood, Vol 115, 2010, pp. 3616-3624. 
68. Song S.N., Tomosugi N., Kawabata H., Ishikawa T., Nishikawa T., Yoshizaki 
.³'RZQ-regulation of hepcidin resulting from long-term treatment with an anti-IL-
6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric 
&DVWOHPDQGLVHDVH´Blood, Vol 116, 2010, pp. 3627-3634.  
69. Hashizume M., Uchiyama Y., HoraL17RPRVXJL10LKDUD0³7RFLOL]XPDE
a humanized antiinterleukin-6 receptor antibody, improved anemia in monkey 
arthritis by suppressing IL-6- LQGXFHGKHSFLGLQSURGXFWLRQ´Rheumatol Int, Vol 30, 
2010, pp. 917-923. 
70. Kroot J.J., Tjalsma H., Fleming R.E., Swinkels D.W³+HSFLGLQLQKXPDQLURQ
GLVRUGHUV GLDJQRVWLF LPSOLFDWLRQV´  Clinical Chemistry, Vol 57, no. 12, 2011, pp. 
1650-1669. 
71. 3LHWUDQJHOR$³+HSFLGLQLQKXPDQLURQGLVRUGHUVWKHUDSHXWLFLPSOLFDWLRQV´J 
Hepatol, Vol 54, 2011, pp. 173-181.  
72. 1HPHWK ( ³+HSFLGLQ ELRORJ\ DQG WKHUDSHXWLF DSSOLFDWLRQV´ Expert Rev 
Hematol, Vol 3, 2010, pp. 153-155. 
73. 5R\ &1 ³$QHPLD RI ,QIODPPDWLRQ´ Hematology Am Soc Hematol Educ 
Program, Vol 2010, 2010, pp. 276-280. 
74. Blanc B., Finch C.A., HallbeUJ / HW DO ³1XWULWLRQDO DQDHPLDV 5HSRUW RI D
:+26FLHQWLILF*URXS´WHO Tech Rep Ser, Vol 405, 1968, pp. 1-40. 
75. $OOHQ /$ )HONHU *0 0HKUD 05 HW DO ³9DOLGDWLRQ DQG SRWHQWLDO
mechanisms of red cell distribution width as a prognostic marker in hHDUWIDLOXUH´J 
Card Fail, Vol 16, 2010, pp. 230-238. 
76. 6NLNQH %6 ³6HUXP WUDQVIHUULQ UHFHSWRU´ Am J Hematol, Vol 83, 2008, pp. 
872-875. 
ANEMIA of INFLAMMATION  
M.Carrabba 59 
 
77. %UXJQDUD&³,URQGHILFLHQF\DQGHU\WKURSRLHVLVQHZGLDJQRVWLFDSSURDFKHV´
Clin Chem, Vol 49, 2003, pp. 1573-1578. 
78. .URRW--.HPQD(+%DQVDO66HWDO ³5HVXOWVRI WKH ILUVW LQWHUQDWLRQDO
round robin for the quantification of urinary and plasma hepcidin assays: need for 
VWDQGDUGL]DWLRQ´Haematologica, Vol 94, 2009, pp. 1748-1752. 
79. Sasu B.J., Li H., Rose M.J., Arvedson T.L., Doellgast G., Molineux G³6HUXP
hepcidin but not prohepcidin may be an effective marker for anemia of 
LQIODPPDWLRQ$,´Blood Cells Mol. Diseases, Vol 45, no. 3, 2010, pp. 238-245. 
80. van Santen S., van Dongen-Lases E.C., de Vegt F., Laarakkers C.M.M., van 
5LHO3/&0YDQ(GH$(DQG6ZLQNHOV':³+HSFLGLQDQGKHPRJORELQFRQWHQW
parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with 
DQHPLD´Arthritits & Rheumatism, Vol 63, no. 12, 2011, pp. 3672-3680. 
81. van Eijk L., Kroot J.J.C., Tromp M., van der Hoeven J.G., Swinkels D.W., 
3LFNNHUV3³,QIODPPDWLRQ-induced hepcidin-25 is associated with the development 
RIDQHPLD LQVHSWLFSDWLHQWVDQREVHUYDWLRQDOVWXG\´Critical Care, Vol 15, 2011, 
pp. R9. 
82. Heming N., Montravers P., Lasocki S³,URQGHILFLHQF\LQFULWLFDOO\LOOSDWLHQWV
KLJKOLJKWLQJWKHUROHRIKHSFLGLQ´Crit care, Vol 15, no. 2, 2011, pp. 210-217.  
83. Swinkels D.W., Girelli D., Laarakkers C., Kroot J., Campostrini N, et al., 
³$GYDQFHV LQ TXDQWLWDWLYH KHSFLGLQ PHDVXUHPHQWV E\ WLPH-of-flight mass 
VSHFWURPHWU\´PLoS One, Vol 3, 2008, pp. e2706.  
84. Campostrini N., Castagna A =DQLQRWWR ) HW DO ³Evaluation of hepcidin 
isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF-
06´J Biomed Biotechnol, Vol 2010, 2010, pp. 329646. 
85. &KRPF]\QVNL 3 6DFFKL 1 ³6LQJOH-step method of RNA isolation by acid 
guanidinium thiocyanate±phenol±FKORURIRUP H[WUDFWLRQ´ Anal Biochem, Vol 162, 
1987, 156-159. 
86. 6FKPLWWJHQ 7' 	 /LYDN .- ³$QDO\V]LQJ UHDO-time PCR data by the 
comparative CT PHWKRG´Nature Protocols, Vol 3, no. 6, 2008, pp. 1101-1108. 
87. Hanley J.A., McNeil B.J³7KHPHDQLQJDQGXVHRIWKHDUHDXQGHUDUHFHLYHU
RSHUDWLQJFKDUDFWHULVWLF52&FXUYH´Radiology, Vol 143, 1982, pp. 29-36. 
88. %HZLFN 9 &KHHN / %DOO - ³6WDWLVWLFV UHYLHZ  UHFHLYHU RSHUDWLQJ
FKDUDFWHULVWLFFXUYHV´Crit Care, Vol 8, 2004, pp. 508-512. 
89. -HONPDQQ:³3URLQIODPPDWRU\F\WRNLQHVORZHULQJHU\WKURSRLHWLQSURGXFWLRQ´
Journal of Interferon and Cytokine Research, Vol 18, 1998, pp. 555-559. 
90. +XQWHU +1 )XOWRQ '% *DQ] 7 9RJHO +- ´The solution structure of 
human hepcidin, a peptide hormone with antimicrobial activity that is involved in 
LURQ XSWDNH DQG KHUHGLWDU\ KHPRFKURPDWRVLV´ J Biol Chem, Vol 277, 2002, pp. 
37597-37603. 
91. %R]]LQL&&DPSRVWULQL17URPELQL31HPHWK(HWDO ³Measurement of 
urinary hepcidin levels by SELDI-TOF-06LQ+)(KHPRFKURPDWRVLV´Blood Cells 
Mol Dis, Vol 40, 2008, pp. 347-352. 
ANEMIA of INFLAMMATION  
M.Carrabba 60 
 
92. Butterfield A.M., Luan P., Witcher D.R., Manetta J., Murphy A.T., Wroblewski 
9- .RQUDG 5- ³$ GXDO PRQRFORQDO VDQGZLFK (/,6$ VSHFLILF IRU KHSFLGLQ-´
Clin Chem, Vol 56, 2010, pp. 1725-1732. 
93. Kato A., Tsuji T., Luo J., Sakao Y., Yasuda H., Hishida A ³$VVRFLDWLRQ RI
prohepcidin and hepcidin-25 with erythropoietin response and ferritin in 
KHPRGLDO\VLVSDWLHQWV´Am J Nephrol, Vol 28, 2008, pp. 115-121. 
94. Ferring-AppHO ' +HQW]H 0: *DO\ % ³&HOO-autonomous and systemic 
context-dependent functions of iron regulatory protein in mammalian iron 
PHWDEROLVP´Blood, Vol 113, 2009, pp. 679-687. 
95. 7DQQR 7 DQG 0LOOHU -/ ³,URQ ORDGLQJ DQG RYHUORDGLQJ GXH WR LQHIIHFWLYH
eU\WKURSRLHVLV´Advances in Hematology, Vol 2010, 2010, pp. 358283. 
96. 5DPLUH] -0 6FKDDG 2 'XUXDO 6 HW DO ³*URZWK GLIIHUHQWLDWLRQ IDFWRU 
production is necessary for normal erythroid differentiation and is increased in 
refractory anaemia with ring-VLGHUREODVWV´British Journal of Haematology, Vol 144, 
no. 2, 2009, pp. 251-262. 
97. .DQGD - 0L]XPRWR & .DZDEDWD + HW DO ³6HUXP KHSFLGLQ OHYHO DQG
HU\WKURSRLHWLF DFWLYLW\ DIWHU KHPDWRSRLHWLF VWHP FHOO WUDQVSODQWDWLRQ´
Haematologica, Vol 93, no. 10, 2008, pp. 1550-1554. 
98. /LX ;% 1JX\HQ 1% 0DUTXHVV .' <DQJ ) +DLOH '- ³5HJXODWLRQ RI
KHSFLGLQDQGIHUURSRUWLQH[SUHVVLRQE\OLSRSRO\VDFFKDULGHLQVSOHQLFPDFURSKDJHV´
Blood Cells Mol and Dis, Vol 35, 2005, pp. 47-56.  
99. Nguyen N.B., Callaghan K.D., *KLR $- +DLOH '- DQG <DQJ ) ³+HSFLGLQ
H[SUHVVLRQ DQG LURQ WUDQVSRUW LQ DOYHRODU PDFURSKDJHV´ Am J Physiol Lung Cell 
Mol Physiol, Vol 291, 2006, pp. L417±L425. 
100. =KDQJ ; DQG 5RYLQ %+ ³+HSFLGLQ H[SUHVVLRQ E\ KXPDQ PRQRF\WHV LQ
response to adhesion and pro-LQIODPPDWRU\F\WRNLQHV´Biochim Biophys Acta, Vol 
1800, 2010, pp. 1262-1267. 
101. :HLVV * DQG  7KHXUO , ³0RQRF\WH KHSFLGLQ DQG WKH DQHPLD RI FKURQLF
GLVHDVH´Blood, Vol 111, no. 7, 2008, pp. 3902-3903. 
102. -DQDUGDQ+3³(OXFLGDWLQJWKHUROHRIPRQRFyte-GHULYHGKHSFLGLQ´Blood, Vol 
111, no. 7, 2008, pp. 3902. 
103. Marsik C., Halama T., Cardona F., Schlifke I., Mittermayer F., Jilma B., 
³(QGRWR[HPLD HQKDQFHV H[SUHVVLRQ RI WKH VLJQDOOLQJ UHFHSWRU JS RQ SURWHLQ
DQGPROHFXODUOHYHO´Clin Immunol, Vol 114, 2005, pp. 293-298. 
104. 1DNDQLVKL7.XUDJDQR7.DLEH61DJDVDZD<+DVXLNH< ³6KRXOGZH
reconsider iron administration based on prevailing ferritin and hepcidin 
FRQFHQWUDWLRQV"´Clin Exp Nephrol, Vol 16, 2012, pp. 819-826. 
 
